Ask OpenScientist

Ask a research question about 46,XX testicular disorder of sex development. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
7
Pathophys.
1
Histopath.
10
Phenotypes
22
Pathograph
5
Genes
3
Medical Actions
2
Subtypes
3
Differentials
14
References
2
Deep Research
🔗

Mappings

MONDO
MONDO:0100249 46,XX testicular disorder of sex development
skos:exactMatch MONDO
Primary MONDO disease identifier for 46,XX testicular disorder of sex development.

Subtypes

2
SRY-positive 46,XX testicular DSD
Most common form (approximately 80% of cases) caused by translocation of the SRY gene from the Y chromosome onto the X chromosome (typically Xp) or rarely onto an autosome. Patients usually have normal external male genitalia and present in adulthood with infertility, azoospermia, small testes, and gynecomastia.
SRY-negative 46,XX testicular DSD
Approximately 20% of cases. Testis differentiation occurs without SRY, typically driven by ectopic activation or duplication of pro-testis genes (SOX9, SOX3) or loss-of-function in pro-ovarian regulators (RSPO1). Patients more often present in childhood with ambiguous external genitalia, cryptorchidism, hypospadias, or ovotesticular tissue.

Pathophysiology

7
Inappropriate activation of testis determination in 46,XX gonad
The shared proximal disease mechanism is activation of the male testis-determination cascade in a chromosomally female (46,XX) gonad, diverting bipotential gonadal precursors toward testicular rather than ovarian differentiation. In SRY-positive cases this is driven by ectopic SRY transferred onto an X chromosome or autosome; in SRY-negative cases pro-testis genes (SOX9, SOX3) are inappropriately overexpressed or pro-ovarian genes (RSPO1) lose function.
Sertoli cell precursor CL:0000216
sex determination GO:0007530 male gonad development GO:0008584 ↑ INCREASED
Show evidence (2 references)
PMID:31336995 SUPPORT Human Clinical
"The SRY gene is identified as the main gene regulating the testes determination cascade. The most important role of SRY is to regulate the SOX9 expression in Sertoli cell precursors. This pathway, in turn, activates testis-specific genes leading to testis determination"
This directly supports inappropriate activation of the SRY/SOX9 testis determination cascade in Sertoli cell precursors as the proximal mechanism in 46,XX testicular DSD.
PMID:36064700 SUPPORT Human Clinical
"SRY-negative 46,XX males show overexpression of pro-testis genes, such as SOX9 and SOX3, or failure of pro-ovarian genes, such as WNT4 and RSPO1, which induces testis differentiation"
This explicitly supports overexpression of pro-testis genes (SOX9, SOX3) or loss of pro-ovarian genes as the mechanism in SRY-negative cases.
SRY translocation onto an X chromosome
The pathognomonic genetic lesion in SRY-positive 46,XX testicular DSD is a Y-to-X translocation during paternal meiosis, producing an X chromosome that carries SRY. The translocated SRY drives the testis determination cascade despite the otherwise female chromosomal complement.
Show evidence (2 references)
PMID:31336995 SUPPORT Human Clinical
"Various studies indicated that 80–90% of 46,XX males result from a Y to X translocation during meiosis"
This supports SRY translocation onto the X chromosome as the dominant causal lesion in SRY-positive 46,XX testicular DSD.
PMID:36341017 SUPPORT Human Clinical
"The presence of the SRY was identified in 130/154 (84.4%) patients: in 98.5% of cases, it was translocated on the Xp chromosome and in 1.5% on an autosome."
This quantifies the dominance of Xp-translocated SRY across a large review cohort.
SOX9 or SOX3 dysregulation in SRY-negative cases
In SRY-negative 46,XX testicular DSD, gain-of-function lesions in pro-testis genes substitute for SRY. Duplications of SOX9 (or its RevSex upstream regulatory element) and ectopic activation of SOX3 (an X-linked SRY paralog) drive testis determination in the absence of SRY.
Show evidence (3 references)
PMID:25077096 SUPPORT Human Clinical
"overexpression of SOX9 leads to the male development of 46,XX gonads in the absence of SRY"
This directly supports SOX9 overexpression as a sufficient driver of testis differentiation in SRY-negative 46,XX testicular DSD.
PMID:34050715 SUPPORT Human Clinical
"whole genome sequencing reported a pathogenic duplication in a non-coding region that contains the RevSex regulatory element, which modifies SOX9 expression and is associated with 46,XX OT-DSD and complete sex reversal"
This identifies cryptic non-coding duplications of the SOX9 RevSex enhancer as a mechanism in SRY-negative cases.
PMID:36064700 SUPPORT Human Clinical
"SOX3 duplication may cause sex reversal, and all 46,XX SRY-negative males should be screened for SOX3 mutations."
This supports SOX3 duplication as a recognized cause of SRY-negative 46,XX testicular DSD.
RSPO1-dependent canonical beta-catenin pro-ovarian signaling loss
In the rare autosomal recessive RSPO1-associated subset of SRY-negative 46,XX testicular DSD, biallelic RSPO1 loss of function reduces canonical beta-catenin signaling that normally promotes female gonadal differentiation. Loss of this pro-ovarian signal permits the 46,XX gonad to enter the testis-determination program.
RSPO1 hgnc:21679
canonical Wnt signaling pathway GO:0060070 ↓ DECREASED female gonad development GO:0008585 ↓ DECREASED
Show evidence (1 reference)
PMID:29575617 SUPPORT Human Clinical
"RSPO1 acts by activating the canonical β-catenin pathway and is one of the most important genes controlling female gonadal differentiation."
This directly supports RSPO1 as an activator of canonical beta-catenin signaling required for female gonadal differentiation.
NR5A1 p.Arg92Trp gonadal fate dysregulation
Recurrent heterozygous NR5A1 p.Arg92Trp variants can shift 46,XX fetal gonadal fate away from stable ovarian differentiation and toward SRY-independent testicular differentiation, probably by reducing female/anti-testis restraint of the male developmental pathway.
NR5A1 hgnc:7983
female gonad development GO:0008585 ↓ DECREASED male gonad development GO:0008584 ↑ INCREASED
Show evidence (2 references)
PMID:27490115 SUPPORT Human Clinical
"We hypothesize that p.(Arg92Trp) results in decreased inhibition of the male developmental pathway through downregulation of female antitestis genes, thereby tipping the balance toward testicular differentiation in 46,XX individuals."
This directly supports the curated NR5A1 mechanism: a recurrent p.Arg92Trp variant reduces anti-testis/pro-ovarian restraint and shifts 46,XX gonadal fate toward testicular differentiation.
PMID:27378692 SUPPORT Human Clinical
"Here, we show that a specific recurrent heterozygous missense mutation (p.Arg92Trp) in the accessory DNA-binding region of NR5A1 is associated with variable degree of testis development in 46,XX children and adults from four unrelated families."
This independent human-family report supports NR5A1 p.Arg92Trp as a molecular switch that can produce testis development in 46,XX individuals.
Dysgenetic testis differentiation
Although ectopic testis-determination signals successfully divert the 46,XX gonad toward testicular development, the absence of the full Y chromosome (and AZF spermatogenesis loci) leaves the resulting testis architecturally abnormal, with progressive loss of germ cells and Sertoli-cell-only seminiferous tubules in the adult.
Sertoli cell CL:0000216 germ cell CL:0000586
spermatogenesis GO:0007283 ∅ ABSENT
Show evidence (1 reference)
PMID:36341017 SUPPORT Human Clinical
"All patients were azoospermic, due to the lack of AZF genetic regions."
This directly links absence of AZF spermatogenesis loci to azoospermia in 46,XX testicular DSD.
Hypergonadotropic hypogonadism and gynecomastia
Compromised testicular steroidogenesis lowers serum testosterone, removes feedback inhibition on the hypothalamic-pituitary axis, and elevates LH and FSH. The relative estrogen excess at puberty contributes to gynecomastia, while inadequate androgen drives small testes, sparse body hair, and reduced fertility.
Leydig cell CL:0000178
steroid hormone biosynthetic process GO:0006694 ↓ DECREASED
Show evidence (1 reference)
PMID:36341017 SUPPORT Human Clinical
"All patients included in the review presented hypergonadotropic hypogonadism."
This directly supports hypergonadotropic hypogonadism as the universal endocrine pattern in 46,XX testicular DSD.

Histopathology

1
Pediatric Gonadal Biopsy Findings
Childhood 46,XX testicular/ovotesticular DSD cohorts can show seminiferous tubule tissue on biopsy, with no overt tumors in the reported cohort but occasional OCT3/4 immunopositivity as a tumor-risk marker.
Show evidence (1 reference)
PMID:40487758 SUPPORT Human Clinical
"A total of 47 children underwent gonadal biopsy and showed no evidence of tumors. However, immunohistochemical analysis revealed that 2 of 16 children were OCT3/4 positive. The most frequent type of gonadal pathology (17/47) was bilateral seminiferous tubules."
This pediatric cohort directly documents the gonadal biopsy pattern and modest tumor-risk-marker positivity in childhood 46,XX testicular/ovotesticular DSD.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for 46,XX testicular disorder of sex development Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

10
Breast 1
Gynecomastia Gynecomastia HP:0000771
Show evidence (1 reference)
PMID:36341017 SUPPORT Human Clinical
"Small testes were the most common clinical characteristic present in 90.2% of the patients, followed by small penis (31.8%), gynecomastia (26.8%) and poor hair distribution (15.4%)."
This documents gynecomastia as a recognized clinical feature, present in roughly a quarter of patients.
Endocrine 1
Hypergonadotropic Hypogonadism Hypergonadotropic hypogonadism HP:0000815
Show evidence (1 reference)
PMID:36341017 SUPPORT Human Clinical
"All patients included in the review presented hypergonadotropic hypogonadism."
This directly supports universal hypergonadotropic hypogonadism as a defining endocrine feature.
Genitourinary 6
Azoospermia Azoospermia HP:0000027
Show evidence (1 reference)
PMID:36341017 SUPPORT Human Clinical
"All patients were azoospermic, due to the lack of AZF genetic regions."
This directly supports azoospermia as a uniform finding in 46,XX testicular DSD.
Decreased Testicular Size Decreased testicular size HP:0008734
Show evidence (1 reference)
PMID:36341017 SUPPORT Human Clinical
"Small testes were the most common clinical characteristic present in 90.2% of the patients"
This directly supports small testes as the most common physical exam finding in 46,XX testicular DSD.
Male Infertility Male infertility HP:0003251
Show evidence (1 reference)
PMID:31336995 SUPPORT Human Clinical
"Male adults with 46,XX and normal external genitalia generally discover their pathology in adulthood because of infertility."
This supports infertility as the most common presenting feature in adults with 46,XX testicular DSD.
Cryptorchidism Cryptorchidism HP:0000028
Show evidence (1 reference)
PMID:31336995 SUPPORT Human Clinical
"Cryptorchidism is present in 15% and anterior hypospadias in around 10%."
This documents cryptorchidism as a recognized phenotype in 46,XX testicular DSD.
Hypospadias Hypospadias HP:0000047
Show evidence (1 reference)
PMID:31336995 SUPPORT Human Clinical
"Cryptorchidism is present in 15% and anterior hypospadias in around 10%."
This supports hypospadias as a recognized urogenital phenotype in 46,XX testicular DSD.
Micropenis Micropenis HP:0000054
Show evidence (1 reference)
PMID:36341017 SUPPORT Human Clinical
"small penis (31.8%)"
The systematic review reports small penis in 31.8% of patients with 46,XX testicular DSD, supporting micropenis as a recognized genitourinary feature of this disorder.
Integument 2
Palmoplantar Keratoderma Palmoplantar keratoderma HP:0000982
Show evidence (1 reference)
PMID:29575617 SUPPORT Human Clinical
"Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal (MIM # 610644) is a clinically distinctive form of SRY-negative 46,XX disorder of sex development."
This directly supports palmoplantar hyperkeratosis as the clinically-distinguishing extra-gonadal feature of the RSPO1-associated SRY-negative subtype.
Squamous Cell Carcinoma of Skin Risk Squamous cell carcinoma of the skin HP:0006739
Show evidence (1 reference)
PMID:29575617 SUPPORT Human Clinical
"Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal (MIM # 610644) is a clinically distinctive form of SRY-negative 46,XX disorder of sex development."
This directly identifies skin squamous cell carcinoma as part of the RSPO1-associated SRY-negative clinical syndrome.
🧬

Genetic Associations

5
SRY (CAUSATIVE)
Gene: SRY hgnc:11311
Show evidence (1 reference)
PMID:36341017 SUPPORT Human Clinical
"Genetic analyses showed translocation of the SRY on Xp chromosome and complete absence of all Azoospermia factor (AZF) genetic regions."
This directly identifies SRY-on-Xp translocation as the causal molecular lesion in SRY-positive cases.
SOX9 (CAUSATIVE)
Gene: SOX9 hgnc:11204
Show evidence (2 references)
PMID:25077096 SUPPORT Human Clinical
"SOX9 duplication has been found to be a rare cause of 46,XX testicular DSD in humans."
This directly establishes SOX9 duplication as a recognized causal mechanism in SRY-negative 46,XX testicular DSD.
PMID:34050715 SUPPORT Human Clinical
"whole genome sequencing reported a pathogenic duplication in a non-coding region that contains the RevSex regulatory element, which modifies SOX9 expression and is associated with 46,XX OT-DSD and complete sex reversal"
This supports cryptic non-coding SOX9 regulatory duplications (RevSex) as a clinically relevant SOX9-pathway mechanism.
SOX3 (CAUSATIVE)
Gene: SOX3 hgnc:11199
Show evidence (1 reference)
PMID:36064700 SUPPORT Human Clinical
"We report the first case of an SRY-negative 46 XX male with prostatic utricle caused by SOX3 duplication."
This directly establishes SOX3 duplication as a causal lesion for SRY-negative 46,XX testicular DSD.
RSPO1 (CAUSATIVE)
Gene: RSPO1 hgnc:21679
Show evidence (1 reference)
PMID:29575617 SUPPORT Human Clinical
"It is a rare autosomal recessive disorder caused due to biallelic loss of function mutations in RSPO1 gene."
This directly identifies biallelic RSPO1 loss-of-function variants as causal in this rare SRY-negative subset.
NR5A1 (CAUSATIVE)
Gene: NR5A1 hgnc:7983
Show evidence (4 references)
PMID:27490115 SUPPORT Human Clinical
"We propose NR5A1, previously associated with 46,XY DSD and 46,XX primary ovarian insufficiency, as a novel gene for 46,XX (ovo)testicular DSD."
This primary human genetics study directly establishes NR5A1 as a disease gene for 46,XX testicular/ovotesticular DSD.
PMID:27378692 SUPPORT Human Clinical
"Here, we show that a specific recurrent heterozygous missense mutation (p.Arg92Trp) in the accessory DNA-binding region of NR5A1 is associated with variable degree of testis development in 46,XX children and adults from four unrelated families."
This independently supports recurrent NR5A1 p.Arg92Trp as a molecular switch that can cause testicular differentiation in 46,XX individuals.
PMID:37189438 SUPPORT Human Clinical
"NR5A1 variants are associated with 46,XY DSD and 46,XX testicular/ovotesticular DSD."
This recent review supports NR5A1 as a recognized gene in the 46,XX testicular/ovotesticular DSD spectrum.
+ 1 more reference
💊

Medical Actions

3
Testosterone Replacement Therapy
Action: testosterone replacement therapy Ontology label: Pharmacotherapy NCIT:C15986
Agent: testosterone CHEBI:17347
Long-term androgen replacement is used to treat hypergonadotropic hypogonadism, support secondary sexual characteristics, and protect bone health in adults with 46,XX testicular DSD.
Show evidence (1 reference)
PMID:31336995 PARTIAL Human Clinical
"the patient may not be able to avoid drug-dependence for maintaining the secondary sex characteristics."
The systematic review describes long-term hormonal management as necessary to maintain secondary sex characteristics in affected patients.
Genetic counseling
Action: Genetic Counseling NCIT:C15240
Genetic counseling is recommended to discuss the rare recurrence risk, fertility limitations, and the need for cytogenetic and targeted molecular testing in family members.
Show evidence (1 reference)
PMID:25077096 SUPPORT Human Clinical
"an effort to make an accurate diagnosis is important for the provision of proper genetic counseling and for guiding patients in their long-term management."
This directly supports genetic counseling as a core management element after molecular diagnosis.
Donor sperm assisted reproduction
Action: in vitro fertilization with donor sperm Ontology label: In Vitro Fertilization NCIT:C16580
Because affected individuals are uniformly azoospermic and testicular sperm extraction is not recommended, in vitro fertilization with donor sperm or adoption are the principal fertility options.
Show evidence (1 reference)
PMID:31336995 SUPPORT Human Clinical
"Testicular sperm extraction is not recommended, and adoption or in vitro fertilization with a sperm donor are fertility options."
This directly supports donor-sperm assisted reproduction as the standard fertility recommendation.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from 46,XX testicular disorder of sex development:

Overlapping Features Klinefelter syndrome (47,XXY) shares small testes, gynecomastia, and hypergonadotropic hypogonadism with 46,XX testicular DSD; the difference is detected by karyotyping (47,XXY versus 46,XX).
Overlapping Features 46,XX gonadal dysgenesis also has a 46,XX karyotype but presents with a female phenotype, streak gonads, primary amenorrhea, and uterine hypoplasia rather than testicular tissue and a male phenotype.
Overlapping Features Congenital adrenal hyperplasia in 46,XX individuals can produce virilization of the external genitalia from prenatal androgen excess but preserves ovarian tissue and is excluded by adrenal hormone testing.
{ }

Source YAML

click to show
name: 46,XX testicular disorder of sex development
creation_date: "2026-05-08T12:00:00Z"
updated_date: "2026-05-08T15:40:44Z"
category: Mendelian
description: >-
  46,XX testicular disorder of sex development (also known as XX male syndrome
  or 46,XX male sex reversal) is a rare disorder of sex development in which
  individuals with a 46,XX karyotype develop testicular tissue and a male
  phenotype. The shared disease mechanism is inappropriate activation of the
  testis-determination pathway in a chromosomally female (46,XX) gonad. In
  approximately 80% of cases this is driven by translocation of the SRY gene
  onto the X chromosome (most often Xp) or, rarely, onto an autosome.
  SRY-negative cases (around 20%) involve gain-of-function lesions of
  pro-testis genes (notably SOX9 or SOX3 duplications) or loss-of-function
  variants in pro-ovarian genes (RSPO1, with biallelic NR5A1 dysregulation also
  contributing in some cases). Affected individuals typically present in
  adulthood with primary infertility, small testes, azoospermia, gynecomastia,
  and hypergonadotropic hypogonadism; SRY-negative cases more often present in
  childhood with ambiguous genitalia. This entry is mechanistically distinct
  from 46,XX gonadal dysgenesis (streak gonads, female phenotype, ovarian
  failure).
disease_term:
  preferred_term: 46,XX testicular disorder of sex development
  term:
    id: MONDO:0100249
    label: 46,XX testicular disorder of sex development
synonyms:
- XX male syndrome
- 46,XX male sex reversal
- 46,XX testicular DSD
- de la Chapelle syndrome
parents:
- Disorder of sex development
- Gonadal development disorder
- Male infertility disorder
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0100249
      label: 46,XX testicular disorder of sex development
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO disease identifier for 46,XX testicular disorder of sex development.
has_subtypes:
- name: SRY-positive
  display_name: SRY-positive 46,XX testicular DSD
  description: >-
    Most common form (approximately 80% of cases) caused by translocation of
    the SRY gene from the Y chromosome onto the X chromosome (typically Xp) or
    rarely onto an autosome. Patients usually have normal external male
    genitalia and present in adulthood with infertility, azoospermia, small
    testes, and gynecomastia.
- name: SRY-negative
  display_name: SRY-negative 46,XX testicular DSD
  description: >-
    Approximately 20% of cases. Testis differentiation occurs without SRY,
    typically driven by ectopic activation or duplication of pro-testis genes
    (SOX9, SOX3) or loss-of-function in pro-ovarian regulators (RSPO1).
    Patients more often present in childhood with ambiguous external genitalia,
    cryptorchidism, hypospadias, or ovotesticular tissue.
prevalence:
- population: General male population
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 5.0
  percentage: "~1:20,000"
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is a rare disease occurring in about 1:20,000 males
    explanation: >-
      This systematic review provides the standard prevalence estimate for
      46,XX testicular DSD.
pathophysiology:
- name: Inappropriate activation of testis determination in 46,XX gonad
  description: >-
    The shared proximal disease mechanism is activation of the male
    testis-determination cascade in a chromosomally female (46,XX) gonad,
    diverting bipotential gonadal precursors toward testicular rather than
    ovarian differentiation. In SRY-positive cases this is driven by ectopic
    SRY transferred onto an X chromosome or autosome; in SRY-negative cases
    pro-testis genes (SOX9, SOX3) are inappropriately overexpressed or
    pro-ovarian genes (RSPO1) lose function.
  cell_types:
  - preferred_term: Sertoli cell precursor
    term:
      id: CL:0000216
      label: Sertoli cell
  biological_processes:
  - preferred_term: sex determination
    term:
      id: GO:0007530
      label: sex determination
  - preferred_term: male gonad development
    term:
      id: GO:0008584
      label: male gonad development
    modifier: INCREASED
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The SRY gene is identified as the main gene regulating the testes
      determination cascade. The most important role of SRY is to regulate the
      SOX9 expression in Sertoli cell precursors. This pathway, in turn,
      activates testis-specific genes leading to testis determination
    explanation: >-
      This directly supports inappropriate activation of the SRY/SOX9 testis
      determination cascade in Sertoli cell precursors as the proximal
      mechanism in 46,XX testicular DSD.
  - reference: PMID:36064700
    reference_title: >-
      Duplication of SOX3 in an SRY-negative 46,XX male with prostatic utricle:
      case report and literature review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SRY-negative 46,XX males show overexpression of pro-testis genes, such
      as SOX9 and SOX3, or failure of pro-ovarian genes, such as WNT4 and
      RSPO1, which induces testis differentiation
    explanation: >-
      This explicitly supports overexpression of pro-testis genes (SOX9, SOX3)
      or loss of pro-ovarian genes as the mechanism in SRY-negative cases.
  downstream:
  - target: Dysgenetic testis differentiation
    description: >-
      Activation of testis-determination programs in 46,XX gonadal tissue
      produces testicular but typically dysgenetic gonads with abnormal
      seminiferous tubule architecture and absent germ cells.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36064700
      reference_title: >-
        Duplication of SOX3 in an SRY-negative 46,XX male with prostatic
        utricle: case report and literature review.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        almost all testicles exhibit dysgenesis
      explanation: >-
        This directly links inappropriate testis-determination signals in 46,XX
        gonads to dysgenetic testicular tissue.
- name: SRY translocation onto an X chromosome
  subtypes:
  - SRY-positive
  description: >-
    The pathognomonic genetic lesion in SRY-positive 46,XX testicular DSD is a
    Y-to-X translocation during paternal meiosis, producing an X chromosome
    that carries SRY. The translocated SRY drives the testis determination
    cascade despite the otherwise female chromosomal complement.
  genes:
  - preferred_term: SRY
    term:
      id: hgnc:11311
      label: SRY
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Various studies indicated that 80–90% of 46,XX males result from a Y to
      X translocation during meiosis
    explanation: >-
      This supports SRY translocation onto the X chromosome as the dominant
      causal lesion in SRY-positive 46,XX testicular DSD.
  - reference: PMID:36341017
    reference_title: >-
      A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
      the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The presence of the SRY was identified in 130/154 (84.4%) patients: in
      98.5% of cases, it was translocated on the Xp chromosome and in 1.5% on
      an autosome.
    explanation: >-
      This quantifies the dominance of Xp-translocated SRY across a large
      review cohort.
  downstream:
  - target: Inappropriate activation of testis determination in 46,XX gonad
    description: >-
      Ectopic SRY translocated onto an X chromosome (or rarely an autosome)
      drives the testis-determination cascade in the otherwise 46,XX gonad,
      producing the inappropriate activation of male sex determination that is
      the proximal disease mechanism in SRY-positive cases.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31336995
      reference_title: >-
        46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
        Systematic Review.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        male sex differentiation is mostly dependent on the presence of the
        SRY gene, which drives the primitive gonads into testes formation
        during early human embryonic development
      explanation: >-
        This supports translocated SRY as the proximate driver of testis
        formation in the 46,XX gonad, instantiating the inappropriate
        testis-determination program.
- name: SOX9 or SOX3 dysregulation in SRY-negative cases
  subtypes:
  - SRY-negative
  description: >-
    In SRY-negative 46,XX testicular DSD, gain-of-function lesions in
    pro-testis genes substitute for SRY. Duplications of SOX9 (or its RevSex
    upstream regulatory element) and ectopic activation of SOX3 (an X-linked
    SRY paralog) drive testis determination in the absence of SRY.
  genes:
  - preferred_term: SOX9
    term:
      id: hgnc:11204
      label: SOX9
  - preferred_term: SOX3
    term:
      id: hgnc:11199
      label: SOX3
  evidence:
  - reference: PMID:25077096
    reference_title: >-
      A Korean boy with 46,XX testicular disorder of sex development caused by
      SOX9 duplication.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      overexpression of SOX9 leads to the male development of 46,XX gonads in
      the absence of SRY
    explanation: >-
      This directly supports SOX9 overexpression as a sufficient driver of
      testis differentiation in SRY-negative 46,XX testicular DSD.
  - reference: PMID:34050715
    reference_title: >-
      Whole genome sequencing identifies a cryptic SOX9 regulatory element
      duplication underlying a case of 46,XX ovotesticular difference of sexual
      development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      whole genome sequencing reported a pathogenic duplication in a
      non-coding region that contains the RevSex regulatory element, which
      modifies SOX9 expression and is associated with 46,XX OT-DSD and complete
      sex reversal
    explanation: >-
      This identifies cryptic non-coding duplications of the SOX9 RevSex
      enhancer as a mechanism in SRY-negative cases.
  - reference: PMID:36064700
    reference_title: >-
      Duplication of SOX3 in an SRY-negative 46,XX male with prostatic utricle:
      case report and literature review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SOX3 duplication may cause sex reversal, and all 46,XX SRY-negative
      males should be screened for SOX3 mutations.
    explanation: >-
      This supports SOX3 duplication as a recognized cause of SRY-negative
      46,XX testicular DSD.
  downstream:
  - target: Inappropriate activation of testis determination in 46,XX gonad
    description: >-
      Gain-of-function dysregulation of pro-testis genes (SOX9 duplication or
      its RevSex enhancer, ectopic SOX3) substitutes for SRY and triggers the
      testis-determination cascade in 46,XX gonadal precursors, producing the
      inappropriate male sex-determination program that defines the
      SRY-negative subtype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25077096
      reference_title: >-
        A Korean boy with 46,XX testicular disorder of sex development caused
        by SOX9 duplication.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        overexpression of SOX9 leads to the male development of 46,XX gonads
        in the absence of SRY
      explanation: >-
        This explicitly supports SOX9 overexpression as a sufficient driver of
        the inappropriate testis-determination program in SRY-negative cases.
- name: RSPO1-dependent canonical beta-catenin pro-ovarian signaling loss
  subtypes:
  - SRY-negative
  description: >-
    In the rare autosomal recessive RSPO1-associated subset of SRY-negative
    46,XX testicular DSD, biallelic RSPO1 loss of function reduces canonical
    beta-catenin signaling that normally promotes female gonadal
    differentiation. Loss of this pro-ovarian signal permits the 46,XX gonad
    to enter the testis-determination program.
  genes:
  - preferred_term: RSPO1
    term:
      id: hgnc:21679
      label: RSPO1
  biological_processes:
  - preferred_term: canonical Wnt signaling pathway
    term:
      id: GO:0060070
      label: canonical Wnt signaling pathway
    modifier: DECREASED
  - preferred_term: female gonad development
    term:
      id: GO:0008585
      label: female gonad development
    modifier: DECREASED
  evidence:
  - reference: PMID:29575617
    reference_title: >-
      Novel RSPO1 mutation causing 46,XX testicular disorder of sex development
      with palmoplantar keratoderma: A review of literature and expansion of
      clinical phenotype.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      RSPO1 acts by activating the canonical β-catenin pathway and is one of
      the most important genes controlling female gonadal differentiation.
    explanation: >-
      This directly supports RSPO1 as an activator of canonical beta-catenin
      signaling required for female gonadal differentiation.
  downstream:
  - target: Inappropriate activation of testis determination in 46,XX gonad
    description: >-
      Loss of RSPO1-dependent canonical beta-catenin pro-ovarian signaling
      removes a female-gonad-determining input, allowing testis differentiation
      in the 46,XX gonad.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced canonical beta-catenin signaling impairs female gonadal differentiation.
    evidence:
    - reference: PMID:29575617
      reference_title: >-
        Novel RSPO1 mutation causing 46,XX testicular disorder of sex
        development with palmoplantar keratoderma: A review of literature and
        expansion of clinical phenotype.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        RSPO1 acts by activating the canonical β-catenin pathway and is one of
        the most important genes controlling female gonadal differentiation.
      explanation: >-
        The snippet supports the intermediate step linking RSPO1 loss to
        impaired pro-ovarian signaling in SRY-negative disease.
  - target: Palmoplantar Keratoderma
    description: >-
      Biallelic RSPO1 loss produces the clinically distinctive SRY-negative
      46,XX DSD subtype with palmoplantar hyperkeratosis/keratoderma.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered RSPO1-dependent canonical beta-catenin signaling in skin
    evidence:
    - reference: PMID:29575617
      reference_title: >-
        Novel RSPO1 mutation causing 46,XX testicular disorder of sex
        development with palmoplantar keratoderma: A review of literature and
        expansion of clinical phenotype.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal (MIM # 610644) is a clinically distinctive form of SRY-negative 46,XX disorder of sex development."
      explanation: >-
        The review identifies palmoplantar hyperkeratosis as part of the
        RSPO1-associated SRY-negative 46,XX DSD syndrome.
  - target: Squamous Cell Carcinoma of Skin Risk
    description: >-
      The RSPO1-associated palmoplantar hyperkeratosis/sex-reversal syndrome
      includes risk of cutaneous squamous cell carcinoma.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered RSPO1-dependent canonical beta-catenin signaling in skin
    evidence:
    - reference: PMID:29575617
      reference_title: >-
        Novel RSPO1 mutation causing 46,XX testicular disorder of sex
        development with palmoplantar keratoderma: A review of literature and
        expansion of clinical phenotype.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal (MIM # 610644) is a clinically distinctive form of SRY-negative 46,XX disorder of sex development."
      explanation: >-
        The review directly includes skin squamous cell carcinoma in the
        RSPO1-associated SRY-negative syndrome.
- name: NR5A1 p.Arg92Trp gonadal fate dysregulation
  subtypes:
  - SRY-negative
  description: >-
    Recurrent heterozygous NR5A1 p.Arg92Trp variants can shift 46,XX fetal
    gonadal fate away from stable ovarian differentiation and toward
    SRY-independent testicular differentiation, probably by reducing
    female/anti-testis restraint of the male developmental pathway.
  genes:
  - preferred_term: NR5A1
    term:
      id: hgnc:7983
      label: NR5A1
  biological_processes:
  - preferred_term: female gonad development
    term:
      id: GO:0008585
      label: female gonad development
    modifier: DECREASED
  - preferred_term: male gonad development
    term:
      id: GO:0008584
      label: male gonad development
    modifier: INCREASED
  evidence:
  - reference: PMID:27490115
    reference_title: >-
      NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular
      disorders of sex development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We hypothesize that p.(Arg92Trp) results in decreased inhibition of the
      male developmental pathway through downregulation of female antitestis
      genes, thereby tipping the balance toward testicular differentiation in
      46,XX individuals.
    explanation: >-
      This directly supports the curated NR5A1 mechanism: a recurrent
      p.Arg92Trp variant reduces anti-testis/pro-ovarian restraint and shifts
      46,XX gonadal fate toward testicular differentiation.
  - reference: PMID:27378692
    reference_title: >-
      A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act
      as a molecular switch in human sex development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we show that a specific recurrent heterozygous missense mutation
      (p.Arg92Trp) in the accessory DNA-binding region of NR5A1 is associated
      with variable degree of testis development in 46,XX children and adults
      from four unrelated families.
    explanation: >-
      This independent human-family report supports NR5A1 p.Arg92Trp as a
      molecular switch that can produce testis development in 46,XX
      individuals.
  downstream:
  - target: Inappropriate activation of testis determination in 46,XX gonad
    description: >-
      Reduced NR5A1-dependent female/anti-testis restraint permits the male
      developmental pathway to dominate in 46,XX gonadal tissue, feeding into
      the shared inappropriate testis-determination program.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Downregulation of female antitestis genes reduces inhibition of the male developmental pathway.
    evidence:
    - reference: PMID:27490115
      reference_title: >-
        NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular
        disorders of sex development.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We hypothesize that p.(Arg92Trp) results in decreased inhibition of the
        male developmental pathway through downregulation of female antitestis
        genes, thereby tipping the balance toward testicular differentiation in
        46,XX individuals.
      explanation: >-
        This supports the causal edge from NR5A1 p.Arg92Trp-mediated loss of
        anti-testis restraint to the shared 46,XX testis-determination
        mechanism.
- name: Dysgenetic testis differentiation
  description: >-
    Although ectopic testis-determination signals successfully divert the 46,XX
    gonad toward testicular development, the absence of the full Y chromosome
    (and AZF spermatogenesis loci) leaves the resulting testis architecturally
    abnormal, with progressive loss of germ cells and Sertoli-cell-only
    seminiferous tubules in the adult.
  cell_types:
  - preferred_term: Sertoli cell
    term:
      id: CL:0000216
      label: Sertoli cell
  - preferred_term: germ cell
    term:
      id: CL:0000586
      label: germ cell
  biological_processes:
  - preferred_term: spermatogenesis
    term:
      id: GO:0007283
      label: spermatogenesis
    modifier: ABSENT
  evidence:
  - reference: PMID:36341017
    reference_title: >-
      A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
      the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients were azoospermic, due to the lack of AZF genetic regions.
    explanation: >-
      This directly links absence of AZF spermatogenesis loci to azoospermia
      in 46,XX testicular DSD.
  downstream:
  - target: Hypergonadotropic hypogonadism and gynecomastia
    description: >-
      Dysgenetic testes produce inadequate testosterone and inhibin, leading to
      compensatory pituitary gonadotropin elevation and a relative imbalance
      that promotes gynecomastia at puberty.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31336995
      reference_title: >-
        46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
        Systematic Review.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Endocrine testing normally reveals hypergonadotropic hypogonadism
        secondary to testicular failure
      explanation: >-
        This directly supports hypergonadotropic hypogonadism as the
        downstream endocrine consequence of dysgenetic testis function.
  - target: Azoospermia
    description: >-
      Dysgenetic 46,XX testes lack the Y-chromosomal AZF regions required for
      spermatogenesis, producing azoospermia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36341017
      reference_title: >-
        A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
        the Literature.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        All patients were azoospermic, due to the lack of AZF genetic regions.
      explanation: >-
        The review directly connects absence of AZF regions in 46,XX
        testicular DSD to azoospermia.
  - target: Decreased Testicular Size
    description: >-
      Dysgenetic testicular development produces small testes, the most common
      clinical finding in the adult presentation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36341017
      reference_title: >-
        A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
        the Literature.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Small testes were the most common clinical characteristic present in
        90.2% of the patients
      explanation: >-
        The review identifies small testes as the most common clinical
        manifestation in 46,XX testicular DSD.
  - target: Male Infertility
    description: >-
      Azoospermia from dysgenetic testes and absent AZF regions causes the
      adult infertility presentation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31336995
      reference_title: >-
        46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
        Systematic Review.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Male adults with 46,XX and normal external genitalia generally discover
        their pathology in adulthood because of infertility.
      explanation: >-
        This supports infertility as the adult presentation downstream of the
        dysgenetic 46,XX testis phenotype.
  - target: Cryptorchidism
    description: >-
      Incompletely masculinized and dysgenetic testicular development can
      include undescended testes, especially in SRY-negative presentations.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - incomplete fetal androgen and testicular descent signaling
    evidence:
    - reference: PMID:31336995
      reference_title: >-
        46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
        Systematic Review.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Cryptorchidism is present in 15% and anterior hypospadias in around 10%.
      explanation: >-
        The systematic review documents cryptorchidism as a recognized
        urogenital phenotype in 46,XX testicular DSD.
  - target: Hypospadias
    description: >-
      Incomplete androgenization of the developing external genitalia can
      produce hypospadias in 46,XX testicular DSD, particularly SRY-negative
      cases.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - incomplete fetal androgen signaling during urethral development
    evidence:
    - reference: PMID:31336995
      reference_title: >-
        46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
        Systematic Review.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Cryptorchidism is present in 15% and anterior hypospadias in around 10%.
      explanation: >-
        The systematic review documents anterior hypospadias as a recognized
        urogenital phenotype in 46,XX testicular DSD.
- name: Hypergonadotropic hypogonadism and gynecomastia
  description: >-
    Compromised testicular steroidogenesis lowers serum testosterone, removes
    feedback inhibition on the hypothalamic-pituitary axis, and elevates LH
    and FSH. The relative estrogen excess at puberty contributes to
    gynecomastia, while inadequate androgen drives small testes, sparse body
    hair, and reduced fertility.
  cell_types:
  - preferred_term: Leydig cell
    term:
      id: CL:0000178
      label: Leydig cell
  biological_processes:
  - preferred_term: steroid hormone biosynthetic process
    term:
      id: GO:0006694
      label: steroid biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:36341017
    reference_title: >-
      A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
      the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients included in the review presented hypergonadotropic
      hypogonadism.
    explanation: >-
      This directly supports hypergonadotropic hypogonadism as the universal
      endocrine pattern in 46,XX testicular DSD.
  downstream:
  - target: Hypergonadotropic Hypogonadism
    description: >-
      Testicular failure lowers sex-steroid feedback and elevates
      gonadotropins, producing hypergonadotropic hypogonadism.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36341017
      reference_title: >-
        A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
        the Literature.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        All patients included in the review presented hypergonadotropic
        hypogonadism.
      explanation: >-
        The review identifies hypergonadotropic hypogonadism as the endocrine
        pattern in all reviewed patients.
  - target: Gynecomastia
    description: >-
      Testicular failure and relative estrogen-androgen imbalance can produce
      gynecomastia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36341017
      reference_title: >-
        A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
        the Literature.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Small testes were the most common clinical characteristic present in
        90.2% of the patients, followed by small penis (31.8%), gynecomastia
        (26.8%) and poor hair distribution (15.4%).
      explanation: >-
        The review reports gynecomastia as a recurrent endocrine/secondary-sex
        phenotype in 46,XX testicular DSD.
  - target: Micropenis
    description: >-
      Inadequate androgen action in the developing or pubertal phenotype can
      produce small penis size.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - incomplete androgen-driven phallic growth
    evidence:
    - reference: PMID:36341017
      reference_title: >-
        A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
        the Literature.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "small penis (31.8%)"
      explanation: >-
        The review reports small penis in nearly one-third of affected
        individuals, supporting micropenis as a downstream androgenization
        phenotype.
phenotypes:
- category: Reproductive
  name: Azoospermia
  description: >-
    Affected individuals are uniformly azoospermic because the 46,XX karyotype
    lacks the AZF spermatogenesis loci required for sperm production.
  diagnostic: true
  phenotype_term:
    preferred_term: azoospermia
    term:
      id: HP:0000027
      label: Azoospermia
  evidence:
  - reference: PMID:36341017
    reference_title: >-
      A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
      the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients were azoospermic, due to the lack of AZF genetic regions.
    explanation: >-
      This directly supports azoospermia as a uniform finding in 46,XX
      testicular DSD.
- category: Reproductive
  name: Decreased Testicular Size
  description: >-
    Small testes are the most common physical finding, reflecting the
    dysgenetic testicular tissue and impaired spermatogenesis.
  diagnostic: true
  phenotype_term:
    preferred_term: decreased testicular size
    term:
      id: HP:0008734
      label: Decreased testicular size
  evidence:
  - reference: PMID:36341017
    reference_title: >-
      A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
      the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Small testes were the most common clinical characteristic present in
      90.2% of the patients
    explanation: >-
      This directly supports small testes as the most common physical exam
      finding in 46,XX testicular DSD.
- category: Endocrine
  name: Hypergonadotropic Hypogonadism
  description: >-
    Reduced testosterone production and elevated FSH and LH define the
    endocrine pattern, reflecting failure of the dysgenetic testes to maintain
    normal steroidogenesis.
  diagnostic: true
  phenotype_term:
    preferred_term: hypergonadotropic hypogonadism
    term:
      id: HP:0000815
      label: Hypergonadotropic hypogonadism
  evidence:
  - reference: PMID:36341017
    reference_title: >-
      A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
      the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients included in the review presented hypergonadotropic
      hypogonadism.
    explanation: >-
      This directly supports universal hypergonadotropic hypogonadism as a
      defining endocrine feature.
- category: Reproductive
  name: Gynecomastia
  description: >-
    Pubertal breast development occurs in a subset of patients, attributed to
    a relatively elevated estrogen:androgen ratio in the setting of testicular
    failure.
  phenotype_term:
    preferred_term: gynecomastia
    term:
      id: HP:0000771
      label: Gynecomastia
  evidence:
  - reference: PMID:36341017
    reference_title: >-
      A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
      the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Small testes were the most common clinical characteristic present in
      90.2% of the patients, followed by small penis (31.8%), gynecomastia
      (26.8%) and poor hair distribution (15.4%).
    explanation: >-
      This documents gynecomastia as a recognized clinical feature, present in
      roughly a quarter of patients.
- category: Reproductive
  name: Male Infertility
  description: >-
    Affected individuals are infertile because of azoospermia from the
    dysgenetic testes; testicular sperm extraction is generally not
    successful.
  diagnostic: true
  phenotype_term:
    preferred_term: male infertility
    term:
      id: HP:0003251
      label: Male infertility
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Male adults with 46,XX and normal external genitalia generally discover
      their pathology in adulthood because of infertility.
    explanation: >-
      This supports infertility as the most common presenting feature in
      adults with 46,XX testicular DSD.
- category: Reproductive
  name: Cryptorchidism
  description: >-
    Cryptorchidism is more common in SRY-negative cases and reflects
    incomplete androgen-driven testicular descent during fetal development.
  subtype: SRY-negative
  phenotype_term:
    preferred_term: cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cryptorchidism is present in 15% and anterior hypospadias in around 10%.
    explanation: >-
      This documents cryptorchidism as a recognized phenotype in 46,XX
      testicular DSD.
- category: Reproductive
  name: Hypospadias
  description: >-
    Hypospadias is more frequent in SRY-negative cases due to incomplete
    androgenization of the developing genital tubercle.
  subtype: SRY-negative
  phenotype_term:
    preferred_term: hypospadias
    term:
      id: HP:0000047
      label: Hypospadias
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cryptorchidism is present in 15% and anterior hypospadias in around 10%.
    explanation: >-
      This supports hypospadias as a recognized urogenital phenotype in 46,XX
      testicular DSD.
- category: Genitourinary
  name: Micropenis
  description: >-
    Small penis size is a recognized clinical feature of 46,XX testicular DSD,
    reflecting incomplete androgen-driven phallic development; cohort data
    report it in approximately one-third of affected individuals.
  phenotype_term:
    preferred_term: Micropenis
    term:
      id: HP:0000054
      label: Micropenis
  evidence:
  - reference: PMID:36341017
    reference_title: >-
      A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
      the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "small penis (31.8%)"
    explanation: >-
      The systematic review reports small penis in 31.8% of patients with
      46,XX testicular DSD, supporting micropenis as a recognized
      genitourinary feature of this disorder.
- category: Dermatological
  name: Palmoplantar Keratoderma
  description: >-
    Biallelic loss-of-function mutations in RSPO1 cause palmoplantar
    hyperkeratosis as a pathognomonic extra-gonadal feature of the
    RSPO1-associated form of SRY-negative 46,XX testicular DSD. Skin
    involvement is the cardinal differentiating finding from other SRY-negative
    causes and is diagnostically informative for the RSPO1 subtype.
  subtype: SRY-negative
  phenotype_term:
    preferred_term: palmoplantar keratoderma
    term:
      id: HP:0000982
      label: Palmoplantar keratoderma
  evidence:
  - reference: PMID:29575617
    reference_title: >-
      Novel RSPO1 mutation causing 46,XX testicular disorder of sex development
      with palmoplantar keratoderma: A review of literature and expansion of
      clinical phenotype.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal (MIM # 610644) is a clinically distinctive form of SRY-negative 46,XX disorder of sex development."
    explanation: >-
      This directly supports palmoplantar hyperkeratosis as the
      clinically-distinguishing extra-gonadal feature of the RSPO1-associated
      SRY-negative subtype.
- category: Dermatological
  name: Squamous Cell Carcinoma of Skin Risk
  description: >-
    RSPO1-associated SRY-negative 46,XX testicular DSD is described as a
    palmoplantar hyperkeratosis syndrome with squamous cell carcinoma of skin,
    making cutaneous carcinoma risk a clinically significant feature of this
    molecular subtype.
  subtype: SRY-negative
  phenotype_term:
    preferred_term: skin squamous cell carcinoma
    term:
      id: HP:0006739
      label: Squamous cell carcinoma of the skin
  evidence:
  - reference: PMID:29575617
    reference_title: >-
      Novel RSPO1 mutation causing 46,XX testicular disorder of sex development
      with palmoplantar keratoderma: A review of literature and expansion of
      clinical phenotype.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal (MIM # 610644) is a clinically distinctive form of SRY-negative 46,XX disorder of sex development."
    explanation: >-
      This directly identifies skin squamous cell carcinoma as part of the
      RSPO1-associated SRY-negative clinical syndrome.
histopathology:
- name: Pediatric Gonadal Biopsy Findings
  description: >-
    Childhood 46,XX testicular/ovotesticular DSD cohorts can show seminiferous
    tubule tissue on biopsy, with no overt tumors in the reported cohort but
    occasional OCT3/4 immunopositivity as a tumor-risk marker.
  evidence:
  - reference: PMID:40487758
    reference_title: >-
      Retrospective analysis of children with 46,XX testicular/ovotesticular
      DSD: a 10-year single-center experience.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A total of 47 children underwent gonadal biopsy and showed no evidence of
      tumors. However, immunohistochemical analysis revealed that 2 of 16
      children were OCT3/4 positive. The most frequent type of gonadal pathology
      (17/47) was bilateral seminiferous tubules.
    explanation: >-
      This pediatric cohort directly documents the gonadal biopsy pattern and
      modest tumor-risk-marker positivity in childhood 46,XX
      testicular/ovotesticular DSD.
genetic:
- name: SRY
  gene_term:
    preferred_term: SRY
    term:
      id: hgnc:11311
      label: SRY
  association: CAUSATIVE
  features: >-
    Translocation of SRY from the Y chromosome onto Xp (most commonly) or
    rarely onto an autosome accounts for approximately 80% of cases of 46,XX
    testicular DSD. The translocated SRY initiates the testis-determination
    cascade and drives a male phenotype despite the 46,XX karyotype.
  subtype: SRY-positive
  evidence:
  - reference: PMID:36341017
    reference_title: >-
      A 46,XX Karyotype in Men with Infertility: Two New Cases and Review of
      the Literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic analyses showed translocation of the SRY on Xp chromosome and
      complete absence of all Azoospermia factor (AZF) genetic regions.
    explanation: >-
      This directly identifies SRY-on-Xp translocation as the causal molecular
      lesion in SRY-positive cases.
- name: SOX9
  gene_term:
    preferred_term: SOX9
    term:
      id: hgnc:11204
      label: SOX9
  association: CAUSATIVE
  features: >-
    SOX9 duplications (including duplications of upstream regulatory elements
    such as RevSex) cause SRY-negative 46,XX testicular and ovotesticular DSD
    by ectopically driving SOX9 expression in 46,XX gonads.
  subtype: SRY-negative
  evidence:
  - reference: PMID:25077096
    reference_title: >-
      A Korean boy with 46,XX testicular disorder of sex development caused by
      SOX9 duplication.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SOX9 duplication has been found to be a rare cause of 46,XX testicular
      DSD in humans.
    explanation: >-
      This directly establishes SOX9 duplication as a recognized causal
      mechanism in SRY-negative 46,XX testicular DSD.
  - reference: PMID:34050715
    reference_title: >-
      Whole genome sequencing identifies a cryptic SOX9 regulatory element
      duplication underlying a case of 46,XX ovotesticular difference of sexual
      development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      whole genome sequencing reported a pathogenic duplication in a
      non-coding region that contains the RevSex regulatory element, which
      modifies SOX9 expression and is associated with 46,XX OT-DSD and complete
      sex reversal
    explanation: >-
      This supports cryptic non-coding SOX9 regulatory duplications (RevSex)
      as a clinically relevant SOX9-pathway mechanism.
- name: SOX3
  gene_term:
    preferred_term: SOX3
    term:
      id: hgnc:11199
      label: SOX3
  association: CAUSATIVE
  features: >-
    Duplications spanning the X-linked SOX3 locus cause SRY-negative 46,XX
    testicular DSD through ectopic SOX3 expression that mimics SRY-driven
    testis determination.
  subtype: SRY-negative
  evidence:
  - reference: PMID:36064700
    reference_title: >-
      Duplication of SOX3 in an SRY-negative 46,XX male with prostatic utricle:
      case report and literature review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report the first case of an SRY-negative 46 XX male with prostatic
      utricle caused by SOX3 duplication.
    explanation: >-
      This directly establishes SOX3 duplication as a causal lesion for
      SRY-negative 46,XX testicular DSD.
- name: RSPO1
  gene_term:
    preferred_term: RSPO1
    term:
      id: hgnc:21679
      label: RSPO1
  association: CAUSATIVE
  features: >-
    Biallelic loss-of-function variants in RSPO1 cause an autosomal recessive
    SRY-negative 46,XX testicular/ovotesticular DSD with palmoplantar
    keratoderma. RSPO1 normally activates canonical WNT/β-catenin signaling
    that promotes ovarian determination; its loss permits ectopic testis
    development.
  subtype: SRY-negative
  evidence:
  - reference: PMID:29575617
    reference_title: >-
      Novel RSPO1 mutation causing 46,XX testicular disorder of sex development
      with palmoplantar keratoderma: A review of literature and expansion of
      clinical phenotype.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is a rare autosomal recessive disorder caused due to biallelic loss
      of function mutations in RSPO1 gene.
    explanation: >-
      This directly identifies biallelic RSPO1 loss-of-function variants as
      causal in this rare SRY-negative subset.
- name: NR5A1
  gene_term:
    preferred_term: NR5A1
    term:
      id: hgnc:7983
      label: NR5A1
  association: CAUSATIVE
  features: >-
    Rare heterozygous NR5A1 p.Arg92Trp variants cause SRY-negative 46,XX
    testicular/ovotesticular DSD by shifting the fetal gonadal regulatory
    balance away from stable ovarian differentiation and toward testicular
    differentiation, with incomplete penetrance and variable expressivity.
  subtype: SRY-negative
  evidence:
  - reference: PMID:27490115
    reference_title: >-
      NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular
      disorders of sex development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We propose NR5A1, previously associated with 46,XY DSD and 46,XX primary
      ovarian insufficiency, as a novel gene for 46,XX (ovo)testicular DSD.
    explanation: >-
      This primary human genetics study directly establishes NR5A1 as a disease
      gene for 46,XX testicular/ovotesticular DSD.
  - reference: PMID:27378692
    reference_title: >-
      A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act
      as a molecular switch in human sex development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we show that a specific recurrent heterozygous missense mutation
      (p.Arg92Trp) in the accessory DNA-binding region of NR5A1 is associated
      with variable degree of testis development in 46,XX children and adults
      from four unrelated families.
    explanation: >-
      This independently supports recurrent NR5A1 p.Arg92Trp as a molecular
      switch that can cause testicular differentiation in 46,XX individuals.
  - reference: PMID:37189438
    reference_title: >-
      Nuclear Receptor Gene Variants Underlying Disorders/Differences of Sex
      Development through Abnormal Testicular Development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NR5A1 variants are associated with 46,XY DSD and 46,XX
      testicular/ovotesticular DSD.
    explanation: >-
      This recent review supports NR5A1 as a recognized gene in the 46,XX
      testicular/ovotesticular DSD spectrum.
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we suggest searching for mutations of other genes involved in the sex
      determination cascade such as SOX9, SOX3, DAX1, WT1, FGF9, and SF1.
    explanation: >-
      This supports SF1 (NR5A1) as a recognized contributory gene in the sex
      determination cascade screened in SRY-negative 46,XX testicular DSD.
treatments:
- name: Testosterone Replacement Therapy
  description: >-
    Long-term androgen replacement is used to treat hypergonadotropic
    hypogonadism, support secondary sexual characteristics, and protect bone
    health in adults with 46,XX testicular DSD.
  treatment_term:
    preferred_term: testosterone replacement therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: testosterone
      term:
        id: CHEBI:17347
        label: testosterone
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the patient may not be able to avoid drug-dependence for maintaining the
      secondary sex characteristics.
    explanation: >-
      The systematic review describes long-term hormonal management as
      necessary to maintain secondary sex characteristics in affected
      patients.
- name: Genetic counseling
  description: >-
    Genetic counseling is recommended to discuss the rare recurrence risk,
    fertility limitations, and the need for cytogenetic and targeted molecular
    testing in family members.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:25077096
    reference_title: >-
      A Korean boy with 46,XX testicular disorder of sex development caused by
      SOX9 duplication.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      an effort to make an accurate diagnosis is important for the provision
      of proper genetic counseling and for guiding patients in their long-term
      management.
    explanation: >-
      This directly supports genetic counseling as a core management element
      after molecular diagnosis.
- name: Donor sperm assisted reproduction
  description: >-
    Because affected individuals are uniformly azoospermic and testicular
    sperm extraction is not recommended, in vitro fertilization with donor
    sperm or adoption are the principal fertility options.
  treatment_term:
    preferred_term: in vitro fertilization with donor sperm
    term:
      id: NCIT:C16580
      label: In Vitro Fertilization
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Testicular sperm extraction is not recommended, and adoption or in vitro
      fertilization with a sperm donor are fertility options.
    explanation: >-
      This directly supports donor-sperm assisted reproduction as the standard
      fertility recommendation.
diagnosis:
- name: Karyotype analysis
  description: >-
    Cytogenetic testing on peripheral blood lymphocytes establishes the 46,XX
    karyotype in a phenotypically male patient and is the cornerstone of
    diagnosis.
  diagnosis_term:
    preferred_term: karyotyping
    term:
      id: MAXO:0001611
      label: karyotyping
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Semen analysis is mandatory and so is the karyotype test.
    explanation: >-
      This supports karyotyping as a mandatory step in diagnosing 46,XX
      testicular DSD.
- name: SRY molecular detection (FISH or PCR)
  description: >-
    Detection and localization of the SRY gene by fluorescence in situ
    hybridization or PCR distinguishes SRY-positive from SRY-negative cases
    and guides further molecular workup.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The investigation is usually based on fluorescence in situ hybridization
      (FISH) or polymerase chain reaction (PCR) amplification of the SRY gene.
    explanation: >-
      This directly supports FISH or PCR for SRY as the standard molecular
      test in 46,XX testicular DSD diagnosis.
- name: Targeted molecular testing for SRY-negative cases
  description: >-
    In SRY-negative patients, targeted screening for duplications and
    pathogenic variants in pro-testis genes (SOX9, SOX3) and pro-ovarian genes
    (RSPO1, with NR5A1 also assessed) is recommended; whole genome sequencing
    can detect cryptic non-coding regulatory duplications such as RevSex.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In SRY-negative patients, no further instrumental or blood tests are
      necessary, however, we suggest searching for mutations of other genes
      involved in the sex determination cascade such as SOX9, SOX3, DAX1, WT1,
      FGF9, and SF1.
    explanation: >-
      This directly recommends gene-panel testing for SOX9, SOX3, and other
      sex-determination pathway genes in SRY-negative cases.
- name: Abdominal ultrasound for Müllerian remnants
  description: >-
    Abdominal ultrasound can be used in the diagnostic workup to evaluate for
    residual Müllerian structures, which may be present in some 46,XX
    testicular DSD presentations.
  diagnosis_term:
    preferred_term: abdominal ultrasound
    term:
      id: NCIT:C19337
      label: Diagnostic Ultrasound
  evidence:
  - reference: PMID:31336995
    reference_title: >-
      46,XX Testicular Disorder of Sex Development (DSD): A Case Report and
      Systematic Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An abdominal ultrasound is useful in order to exclude residual Müllerian
      structures.
    explanation: >-
      This supports abdominal ultrasound as a diagnostic procedure for checking
      residual Müllerian structures in 46,XX testicular DSD workup.
differential_diagnoses:
- name: Klinefelter syndrome
  description: >-
    Klinefelter syndrome (47,XXY) shares small testes, gynecomastia, and
    hypergonadotropic hypogonadism with 46,XX testicular DSD; the difference
    is detected by karyotyping (47,XXY versus 46,XX).
  disease_term:
    preferred_term: Klinefelter syndrome
    term:
      id: MONDO:0006823
      label: Klinefelter syndrome
- name: 46,XX gonadal dysgenesis
  description: >-
    46,XX gonadal dysgenesis also has a 46,XX karyotype but presents with a
    female phenotype, streak gonads, primary amenorrhea, and uterine
    hypoplasia rather than testicular tissue and a male phenotype.
  disease_term:
    preferred_term: 46,XX gonadal dysgenesis
    term:
      id: MONDO:0009299
      label: 46 XX gonadal dysgenesis
- name: Congenital adrenal hyperplasia
  description: >-
    Congenital adrenal hyperplasia in 46,XX individuals can produce
    virilization of the external genitalia from prenatal androgen excess but
    preserves ovarian tissue and is excluded by adrenal hormone testing.
  disease_term:
    preferred_term: congenital adrenal hyperplasia
    term:
      id: MONDO:0018479
      label: congenital adrenal hyperplasia
clinical_trials: []
datasets: []
notes: >-
  PubMed-driven curation was expanded with Falcon deep research on 2026-05-30.
  Falcon findings were treated as leads and only incorporated when independently
  verified against fetched reference caches.
references:
- reference: DOI:10.1038/gim.2016.118
  title: NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular disorders of sex development
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings:
  - statement: NR5A1 is a disease gene for 46,XX testicular/ovotesticular DSD.
    supporting_text: >-
      We propose NR5A1, previously associated with 46,XY DSD and 46,XX primary
      ovarian insufficiency, as a novel gene for 46,XX (ovo)testicular DSD.
    evidence:
    - reference: PMID:27490115
      reference_title: >-
        NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular
        disorders of sex development.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We propose NR5A1, previously associated with 46,XY DSD and 46,XX primary
        ovarian insufficiency, as a novel gene for 46,XX (ovo)testicular DSD.
      explanation: Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
- reference: DOI:10.1093/hmg/ddw186
  title: A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act as a molecular switch in human sex development
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings:
  - statement: Recurrent NR5A1 p.Arg92Trp can switch 46,XX gonadal fate toward testis development.
    supporting_text: >-
      Here, we show that a specific recurrent heterozygous missense mutation
      (p.Arg92Trp) in the accessory DNA-binding region of NR5A1 is associated
      with variable degree of testis development in 46,XX children and adults
      from four unrelated families.
    evidence:
    - reference: PMID:27378692
      reference_title: >-
        A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act
        as a molecular switch in human sex development.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Here, we show that a specific recurrent heterozygous missense mutation
        (p.Arg92Trp) in the accessory DNA-binding region of NR5A1 is associated
        with variable degree of testis development in 46,XX children and adults
        from four unrelated families.
      explanation: Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
- reference: DOI:10.1159/000445088
  title: 'Disorders of Sex Development with Testicular Differentiation in SRY-Negative 46,XX Individuals: Clinical and Genetic Aspects'
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings: []
- reference: DOI:10.1186/1471-2490-14-104
  title: '46,XX testicular disorder of sexual development with SRY-negative caused by some unidentified mechanisms: a case report and review of the literature'
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings: []
- reference: DOI:10.1186/s12920-022-01347-0
  title: 'Duplication of SOX3 in an SRY-negative 46,XX male with prostatic utricle: case report and literature review'
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings: []
- reference: DOI:10.1371/journal.pone.0186331
  title: XX Disorder of Sex Development is associated with an insertion on chromosome 9 and downregulation of RSPO1 in dogs (Canis lupus familiaris)
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings: []
- reference: DOI:10.1530/eje-18-0256
  title: 'GENETICS IN ENDOCRINOLOGY: Approaches to molecular genetic diagnosis in the management of differences/disorders of sex development (DSD): position paper of EU COST Action BM 1303 DSDnet'
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings: []
- reference: DOI:10.23736/s2724-5276.21.06512-5
  title: 'Differences of sex development in the newborn: from clinical scenario to molecular diagnosis'
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings: []
- reference: DOI:10.3389/fendo.2024.1354759
  title: Diagnosis and management of non-CAH 46,XX disorders/differences in sex development
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings:
  - statement: Non-CAH 46,XX testicular/ovotesticular DSD has a broad sex-determination gene list.
    supporting_text: >-
      Many genes are involved in the mechanisms of gonadal development, and
      genes associated with 46,XX T/OT-DSD include translocations of the SRY;
      copy number variants in NR2F2, NR0B1, SOX3, SOX9, SOX10, and FGF9, and
      sequence variants in NR5A1, NR2F2, RSPO1, SOX9, WNT2B, WNT4, and WT1.
    evidence:
    - reference: PMID:38812815
      reference_title: Diagnosis and management of non-CAH 46,XX disorders/differences in sex development.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Many genes are involved in the mechanisms of gonadal development, and
        genes associated with 46,XX T/OT-DSD include translocations of the SRY;
        copy number variants in NR2F2, NR0B1, SOX3, SOX9, SOX10, and FGF9, and
        sequence variants in NR5A1, NR2F2, RSPO1, SOX9, WNT2B, WNT4, and WT1.
      explanation: Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
- reference: DOI:10.3389/fendo.2024.1385901
  title: 'Testicular differentiation in 46,XX DSD: an overview of genetic causes'
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings:
  - statement: Many 46,XX testicular/ovotesticular DSD cases remain genetically unresolved.
    supporting_text: >-
      However, it is important to note that a significant number of patients
      with these DSD conditions have not yet recognized a genetic diagnosis.
    evidence:
    - reference: PMID:38721146
      reference_title: 'Testicular differentiation in 46,XX DSD: an overview of genetic causes.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        However, it is important to note that a significant number of patients
        with these DSD conditions have not yet recognized a genetic diagnosis.
      explanation: Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
- reference: DOI:10.3389/fendo.2025.1571467
  title: 'Retrospective analysis of children with 46,XX testicular/ovotesticular DSD: a 10-year single-center experience'
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings:
  - statement: Pediatric 46,XX testicular/ovotesticular DSD can show biopsy seminiferous tubules and modest OCT3/4 tumor-risk-marker positivity.
    supporting_text: >-
      A total of 47 children underwent gonadal biopsy and showed no evidence of
      tumors. However, immunohistochemical analysis revealed that 2 of 16
      children were OCT3/4 positive. The most frequent type of gonadal pathology
      (17/47) was bilateral seminiferous tubules.
    evidence:
    - reference: PMID:40487758
      reference_title: >-
        Retrospective analysis of children with 46,XX testicular/ovotesticular
        DSD: a 10-year single-center experience.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        A total of 47 children underwent gonadal biopsy and showed no evidence
        of tumors. However, immunohistochemical analysis revealed that 2 of 16
        children were OCT3/4 positive. The most frequent type of gonadal
        pathology (17/47) was bilateral seminiferous tubules.
      explanation: Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
- reference: DOI:10.3389/fendo.2026.1829751
  title: 'Rare SRY-negative 46,XX disorder of sex development with male phenotype and ectopic gonads: a case report'
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings: []
- reference: DOI:10.3390/biom13040691
  title: Nuclear Receptor Gene Variants Underlying Disorders/Differences of Sex Development through Abnormal Testicular Development
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings:
  - statement: NR5A1, NR0B1, and NR2F2 nuclear-receptor variants are part of atypical testicular-development DSD mechanisms.
    supporting_text: >-
      To date, pathogenic variants of three nuclear receptor genes (NR5A1,
      NR0B1, and NR2F2) have been reported to cause DSD via atypical testicular
      development.
    evidence:
    - reference: PMID:37189438
      reference_title: >-
        Nuclear Receptor Gene Variants Underlying Disorders/Differences of Sex
        Development through Abnormal Testicular Development.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        To date, pathogenic variants of three nuclear receptor genes (NR5A1,
        NR0B1, and NR2F2) have been reported to cause DSD via atypical
        testicular development.
      explanation: Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
- reference: DOI:10.3390/medicina55070371
  title: '46,XX Testicular Disorder of Sex Development (DSD): A Case Report and Systematic Review'
  found_in:
  - 46_XX_Testicular_DSD-deep-research-falcon.md
  findings: []
📚

References & Deep Research

References

14
NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular disorders of sex development
1 finding
NR5A1 is a disease gene for 46,XX testicular/ovotesticular DSD.
"We propose NR5A1, previously associated with 46,XY DSD and 46,XX primary ovarian insufficiency, as a novel gene for 46,XX (ovo)testicular DSD."
Show evidence (1 reference)
PMID:27490115 SUPPORT Human Clinical
"We propose NR5A1, previously associated with 46,XY DSD and 46,XX primary ovarian insufficiency, as a novel gene for 46,XX (ovo)testicular DSD."
Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act as a molecular switch in human sex development
1 finding
Recurrent NR5A1 p.Arg92Trp can switch 46,XX gonadal fate toward testis development.
"Here, we show that a specific recurrent heterozygous missense mutation (p.Arg92Trp) in the accessory DNA-binding region of NR5A1 is associated with variable degree of testis development in 46,XX children and adults from four unrelated families."
Show evidence (1 reference)
PMID:27378692 SUPPORT Human Clinical
"Here, we show that a specific recurrent heterozygous missense mutation (p.Arg92Trp) in the accessory DNA-binding region of NR5A1 is associated with variable degree of testis development in 46,XX children and adults from four unrelated families."
Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
Disorders of Sex Development with Testicular Differentiation in SRY-Negative 46,XX Individuals: Clinical and Genetic Aspects
No top-level findings curated for this source.
46,XX testicular disorder of sexual development with SRY-negative caused by some unidentified mechanisms: a case report and review of the literature
No top-level findings curated for this source.
Duplication of SOX3 in an SRY-negative 46,XX male with prostatic utricle: case report and literature review
No top-level findings curated for this source.
XX Disorder of Sex Development is associated with an insertion on chromosome 9 and downregulation of RSPO1 in dogs (Canis lupus familiaris)
No top-level findings curated for this source.
GENETICS IN ENDOCRINOLOGY: Approaches to molecular genetic diagnosis in the management of differences/disorders of sex development (DSD): position paper of EU COST Action BM 1303 DSDnet
No top-level findings curated for this source.
Differences of sex development in the newborn: from clinical scenario to molecular diagnosis
No top-level findings curated for this source.
Diagnosis and management of non-CAH 46,XX disorders/differences in sex development
1 finding
Non-CAH 46,XX testicular/ovotesticular DSD has a broad sex-determination gene list.
"Many genes are involved in the mechanisms of gonadal development, and genes associated with 46,XX T/OT-DSD include translocations of the SRY; copy number variants in NR2F2, NR0B1, SOX3, SOX9, SOX10, and FGF9, and sequence variants in NR5A1, NR2F2, RSPO1, SOX9, WNT2B, WNT4, and WT1."
Show evidence (1 reference)
PMID:38812815 SUPPORT Human Clinical
"Many genes are involved in the mechanisms of gonadal development, and genes associated with 46,XX T/OT-DSD include translocations of the SRY; copy number variants in NR2F2, NR0B1, SOX3, SOX9, SOX10, and FGF9, and sequence variants in NR5A1, NR2F2, RSPO1, SOX9, WNT2B, WNT4, and WT1."
Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
Testicular differentiation in 46,XX DSD: an overview of genetic causes
1 finding
Many 46,XX testicular/ovotesticular DSD cases remain genetically unresolved.
"However, it is important to note that a significant number of patients with these DSD conditions have not yet recognized a genetic diagnosis."
Show evidence (1 reference)
PMID:38721146 SUPPORT Human Clinical
"However, it is important to note that a significant number of patients with these DSD conditions have not yet recognized a genetic diagnosis."
Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
Retrospective analysis of children with 46,XX testicular/ovotesticular DSD: a 10-year single-center experience
1 finding
Pediatric 46,XX testicular/ovotesticular DSD can show biopsy seminiferous tubules and modest OCT3/4 tumor-risk-marker positivity.
"A total of 47 children underwent gonadal biopsy and showed no evidence of tumors. However, immunohistochemical analysis revealed that 2 of 16 children were OCT3/4 positive. The most frequent type of gonadal pathology (17/47) was bilateral seminiferous tubules."
Show evidence (1 reference)
PMID:40487758 SUPPORT Human Clinical
"A total of 47 children underwent gonadal biopsy and showed no evidence of tumors. However, immunohistochemical analysis revealed that 2 of 16 children were OCT3/4 positive. The most frequent type of gonadal pathology (17/47) was bilateral seminiferous tubules."
Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
Rare SRY-negative 46,XX disorder of sex development with male phenotype and ectopic gonads: a case report
No top-level findings curated for this source.
Nuclear Receptor Gene Variants Underlying Disorders/Differences of Sex Development through Abnormal Testicular Development
1 finding
NR5A1, NR0B1, and NR2F2 nuclear-receptor variants are part of atypical testicular-development DSD mechanisms.
"To date, pathogenic variants of three nuclear receptor genes (NR5A1, NR0B1, and NR2F2) have been reported to cause DSD via atypical testicular development."
Show evidence (1 reference)
PMID:37189438 SUPPORT Human Clinical
"To date, pathogenic variants of three nuclear receptor genes (NR5A1, NR0B1, and NR2F2) have been reported to cause DSD via atypical testicular development."
Deep research cited this publication as relevant literature for 46 XX Testicular DSD.
46,XX Testicular Disorder of Sex Development (DSD): A Case Report and Systematic Review
No top-level findings curated for this source.

Deep Research

2
Falcon
46,XX Testicular Disorder of Sex Development (46,XX T-DSD): Disease Characteristics Research Report
Edison Scientific Literature 33 citations 2026-05-30T01:38:39.620093

46,XX Testicular Disorder of Sex Development (46,XX T-DSD): Disease Characteristics Research Report

Target disease

Disease name: 46,XX testicular disorder of sex development (46,XX testicular DSD; “XX male syndrome”).

Note on identifiers (OMIM/Orphanet/MONDO/MeSH/ICD): In this tool-run, primary ontology/registry pages (OMIM/Orphanet/MONDO/ICD/MeSH) were not directly retrievable as citable full-text sources. Consequently, identifier assertions are not provided here to avoid uncited/uncertain mappings. The report below is built from peer‑reviewed primary literature and recent reviews.


1. Disease information

1.1 Concise overview

46,XX testicular DSD is a rare condition in which an individual with a 46,XX karyotype develops testicular tissue and typically a male or undervirilized male phenotype. It is commonly diagnosed after puberty/adulthood during evaluation for infertility and/or hypogonadism. (terribile201946xxtesticulardisorder pages 1-3, ferrari2024testiculardifferentiationin pages 1-2)

1.2 Synonyms / alternative names

Frequently used names include “46,XX testicular DSD,” “46,XX male syndrome,” “XX male syndrome,” and, in newer nomenclature, “46,XX testicular difference of sex development.” (li201446xxtesticulardisorder pages 1-2, terribile201946xxtesticulardisorder pages 1-3)

1.3 Evidence source type

Most evidence for this condition derives from aggregated case series and systematic reviews (adult infertility presentations) plus single‑center pediatric cohorts for early/ambiguous genitalia presentations, and mechanistic inference from human genetics and animal models. (terribile201946xxtesticulardisorder pages 1-3, gong2025retrospectiveanalysisof pages 1-2, ferrari2024testiculardifferentiationin pages 2-4)


2. Etiology

2.1 Primary causal factors (genetic/mechanistic)

The disease is primarily genetic and arises from dysregulation of the early gonadal sex‑determination network, which can be conceptualized as competition between: - a pro‑testis pathway centered on SRY → SOX9 activation and reinforcement; and - a pro‑ovary/anti‑testis pathway centered on RSPO1/WNT4/β‑catenin (CTNNB1) and FOXL2. (ferrari2024testiculardifferentiationin pages 2-4, abalı2024diagnosisandmanagement pages 1-2)

A. SRY translocation (most common)

A large fraction of 46,XX testicular DSD is due to translocation of Y‑chromosomal material including SRY (typically to Xp or an autosome), which triggers testis determination despite an XX karyotype. Reviews commonly report ~80–90% SRY‑positive. (terribile201946xxtesticulardisorder pages 7-9, terribile201946xxtesticulardisorder pages 1-3)

Direct abstract quote (systematic review context): “The patients generally have normal external genitalia and discover their pathology in adulthood because of infertility… The sex-determining region Y (SRY) gene was detected in 51/57 cases.” (Terribile 2019, Medicina; published 2019-07; URL https://doi.org/10.3390/medicina55070371) (terribile201946xxtesticulardisorder pages 1-3)

B. SRY‑negative mechanisms (minority, heterogeneous)

SRY‑negative 46,XX testicular/ovotesticular DSD is attributed to (i) gain of function/overexpression of pro‑testis genes or (ii) loss of function of pro‑ovary/anti‑testis genes, though many cases remain unsolved. (ferrari2024testiculardifferentiationin pages 2-4, abalı2024diagnosisandmanagement pages 1-2)

Direct abstract quotes supporting these two broad categories: - “SRY-negative 46,XX males show overexpression of pro-testis genes, such as SOX9 and SOX3, or failure of pro-ovarian genes, such as WNT4 and RSPO1, which induces testis differentiation…” (Wei 2022, BMC Med Genomics; published 2022-09; URL https://doi.org/10.1186/s12920-022-01347-0) (wei2022duplicationofsox3 pages 1-3) - “Genes associated with 46,XX T/OT-DSD include translocations of the SRY; copy number variants in NR2F2, NR0B1, SOX3, SOX9, SOX10, and FGF9, and sequence variants in NR5A1, NR2F2, RSPO1, SOX9, WNT2B, WNT4, and WT1.” (Abalı & Guran 2024, Front Endocrinol; published 2024-05; URL https://doi.org/10.3389/fendo.2024.1354759) (abalı2024diagnosisandmanagement pages 1-2)

C. Copy-number variants / structural variation affecting SOX genes

SRY‑negative cases can result from structural variants affecting gene dosage/regulatory architecture of SOX genes (e.g., SOX3 duplication). A reported SRY‑negative case had a 1.4 Mb duplication involving SOX3, with a recommendation to screen SOX3 in SRY‑negative XX males. (wei2022duplicationofsox3 pages 1-3)

D. NR5A1 (SF‑1) recurrent variant as a molecular “switch”

A key non‑SRY mechanism is the recurrent NR5A1 p.Arg92Trp variant, which has been identified in multiple unrelated 46,XX (ovo)testicular DSD individuals after excluding SRY translocation and CNVs. (baetens2017nr5a1isa pages 1-2, bashamboo2016arecurrentp.arg92trp pages 1-3)

Direct abstract quote: “A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act as a molecular switch in human sex development.” (Bashamboo 2016, Hum Mol Genet; published 2016-07; URL https://doi.org/10.1093/hmg/ddw186) (bashamboo2016arecurrentp.arg92trp pages 1-3)

Mechanistic interpretation from a Genetics in Medicine study: the variant is hypothesized to bias fate by “decreased inhibition of the male developmental pathway through downregulation of female antitestis genes,” tipping the balance toward testicular differentiation in 46,XX individuals. (Baetens 2017, Genet Med; published 2017-04; URL https://doi.org/10.1038/gim.2016.118) (baetens2017nr5a1isa pages 1-2)

2.2 Risk factors

Genetic risk factor: presence of SRY translocation or pathogenic variants/CNVs in the sex‑determination network genes noted above is causal rather than merely predisposing. (terribile201946xxtesticulardisorder pages 7-9, abalı2024diagnosisandmanagement pages 1-2)

Environmental risk factors: For 46,XX testicular DSD specifically, the dominant causes are genetic; exogenous androgen exposure more strongly pertains to other 46,XX DSD categories (e.g., CAH or maternal androgen exposure), rather than XX testicular differentiation. (abalı2024diagnosisandmanagement pages 1-2)

2.3 Protective factors / gene–environment interactions

No specific protective factors or gene–environment interactions are established for XX testicular DSD in the sources retrieved here.


3. Phenotypes

3.1 Core phenotype spectrum (with suggested HPO terms)

Phenotype is variable, ranging from typical male external genitalia to ambiguous genitalia, often with gonadal dysgenesis and infertility.

Commonly reported features include: - Azoospermia / infertility (HP:0000027 Azoospermia; HP:0000789 Infertility) (li201446xxtesticulardisorder pages 1-2, terribile201946xxtesticulardisorder pages 1-3) - Hypergonadotropic hypogonadism / primary testicular failure (HP:0000044 Hypogonadotropic hypogonadism is not appropriate; consider HP:0000044?; better: HP:0000035 Hypergonadotropic hypogonadism; HP:0000035; and lab: increased LH/FSH) (terribile201946xxtesticulardisorder pages 7-9, li201446xxtesticulardisorder pages 1-2) - Small testes / microorchidism (HP:0000028 Microorchidism; HP:0000007 Cryptorchidism) (terribile201946xxtesticulardisorder pages 7-9, li201446xxtesticulardisorder pages 1-2) - Hypospadias (HP:0000047 Hypospadias) (terribile201946xxtesticulardisorder pages 7-9, li201446xxtesticulardisorder pages 1-2) - Gynecomastia (HP:0000774 Gynecomastia) (terribile201946xxtesticulardisorder pages 7-9, li201446xxtesticulardisorder pages 1-2) - Residual Müllerian structures / prostatic utricle (subset, especially SRY-negative/undervirilized) (HP:0000132 Abnormality of uterus / persistent Müllerian structures; note this is phenotype-dependent) (wei2022duplicationofsox3 pages 1-3, terribile201946xxtesticulardisorder pages 9-11)

Direct abstract quote summarizing the common adult presentation pattern: “The patients generally have normal external genitalia and discover their pathology in adulthood because of infertility.” (Terribile 2019; URL https://doi.org/10.3390/medicina55070371) (terribile201946xxtesticulardisorder pages 1-3)

3.2 Age of onset and progression

  • Congenital onset at gonadal differentiation (fetal), but ascertainment is often later.
  • Ferrari et al. summarize that ~80% have typical male genitalia at birth with diagnosis often after puberty due to gynecomastia/hypogonadism/infertility. (ferrari2024testiculardifferentiationin pages 1-2)
  • A subset presents in infancy/childhood with ambiguous genitalia; in a pediatric cohort the median age at first presentation was 18 months. (gong2025retrospectiveanalysisof pages 1-2)

3.3 Frequency / statistics from published cohorts

From an adult systematic review (selected phenotypes across published cases): - cryptorchidism (~15%) and anterior hypospadias (~10%) were cited as non‑rare genital findings; hypergonadotropic hypogonadism was common. (terribile201946xxtesticulardisorder pages 7-9)

Pediatric single‑center cohort (46,XX testicular/ovotesticular DSD; n=52): - median age at presentation: 18 months - SRY in peripheral blood: 4/52; SRY in tissue (tested n=8): 0/8 - gonadal biopsy performed: 47/52; most frequent pathology: bilateral seminiferous tubules 17/47 - tumor marker: OCT3/4 positive 2/16 by immunohistochemistry; no tumors observed in biopsies - male‑reared adolescents: puberty onset ~12 ± 0.87 years; basal LH 6.44 ± 4.19 IU/L, FSH 13.18 ± 10.22 IU/L, testosterone 3.40 ± 1.63 nmol/L (gong2025retrospectiveanalysisof pages 1-2)


4. Genetic / molecular information

4.1 Causal genes and variant classes (evidence-based list)

Evidence-supported genes implicated in 46,XX testicular/ovotesticular DSD across the retrieved 2024 review literature include: - SRY (usually via translocation) (terribile201946xxtesticulardisorder pages 7-9, abalı2024diagnosisandmanagement pages 1-2) - NR5A1 (SF-1) sequence variants (notably p.Arg92Trp) (baetens2017nr5a1isa pages 1-2, bashamboo2016arecurrentp.arg92trp pages 1-3) - SOX9 / SOX3 / SOX10 CNVs/structural variants causing overexpression/positional effects (wei2022duplicationofsox3 pages 1-3, abalı2024diagnosisandmanagement pages 1-2) - RSPO1, WNT4 loss-of-function in the pro-ovary pathway (ferrari2024testiculardifferentiationin pages 2-4, abalı2024diagnosisandmanagement pages 1-2) - Other genes named in reviews: NR2F2, NR0B1, FGF9, WT1, WNT2B (abalı2024diagnosisandmanagement pages 1-2)

4.2 Mechanistic chain (current understanding)

A simplified causal chain: 1. Primary genetic change: (a) SRY translocation or (b) SRY-independent activation of SOX9 (via SOX gene dosage/NR5A1 changes) or (c) impaired ovarian-maintenance signaling (RSPO1/WNT4/β‑catenin/FOXL2). (ferrari2024testiculardifferentiationin pages 2-4, abalı2024diagnosisandmanagement pages 1-2, baetens2017nr5a1isa pages 1-2) 2. Cell fate shift in fetal bipotential gonad: increased Sertoli-lineage program (SOX9/FGF9/PGD2 reinforcement) and/or reduced granulosa/ovary program. (ferrari2024testiculardifferentiationin pages 2-4, hattori2023nuclearreceptorgene pages 1-3) 3. Testicular tissue differentiation (often dysgenetic) → androgen/AMH signaling patterns that shape internal/external genital development. 4. Postnatal outcomes: variable genital phenotype; progressive primary testicular failure leading to hypergonadotropic hypogonadism and infertility/azoospermia. (terribile201946xxtesticulardisorder pages 7-9, li201446xxtesticulardisorder pages 1-2)

4.3 Variant interpretation and “unknowns”

A substantial fraction of SRY-negative cases remain without a molecular diagnosis, suggesting unrecognized genetic/epigenetic mechanisms. Ferrari 2024 emphasizes that “a significant number of patients… have not yet recognized a genetic diagnosis.” (Ferrari 2024; URL https://doi.org/10.3389/fendo.2024.1385901) (ferrari2024testiculardifferentiationin pages 1-2)


5. Environmental information

Environmental causes are not a primary driver for 46,XX testicular DSD in the retrieved literature. Reviews of non‑CAH 46,XX DSD focus mainly on genetic etiologies and distinguish androgen‑excess disorders (CAH, aromatase deficiency, glucocorticoid resistance) from testicular/ovotesticular differentiation disorders. (abalı2024diagnosisandmanagement pages 1-2)


6. Mechanism / pathophysiology

6.1 Pathways (suggested pathway/ontology anchors)

Key antagonistic modules: - Pro-testis module: SRY → SOX9; reinforced by FGF9 and PGD2; includes NR5A1 as a core gonadal regulator. (ferrari2024testiculardifferentiationin pages 2-4, hattori2023nuclearreceptorgene pages 1-3) - Pro-ovary/anti-testis module: RSPO1/WNT4 → β‑catenin (CTNNB1); FOXL2 required for ovarian development/maintenance. (ferrari2024testiculardifferentiationin pages 2-4)

Suggested GO biological process terms (examples for knowledge base annotation): - GO:0007530 sex determination - GO:0007281 germ cell development - GO:0007548 sex differentiation - GO:0001701 in utero embryonic development

Suggested Cell Ontology (CL) terms: - CL:0000011 Sertoli cell - CL:0000178 Leydig cell - CL:0002338 granulosa cell

6.2 Tumor biology / surveillance markers

In a pediatric cohort (n=52), gonadal biopsy showed no tumors, but OCT3/4 positivity (a germ‑cell tumor risk marker) was observed in 2/16 tested by immunohistochemistry, suggesting the need for individualized tumor-risk assessment in some cases. (gong2025retrospectiveanalysisof pages 1-2)


7. Anatomical structures affected

7.1 Primary organs and structures

  • Gonads (testes/ovotestes, often dysgenetic) (UBERON:0000473 testis; UBERON:0000992 ovary—coexistence in OT‑DSD)
  • Internal genital tract may include variable Müllerian remnants (uterus/fallopian tubes) in some SRY-negative/ambiguous presentations. (terribile201946xxtesticulardisorder pages 9-11, wei2022duplicationofsox3 pages 1-3)
  • External genitalia range from typical male to ambiguous (hypospadias, micropenis). (terribile201946xxtesticulardisorder pages 7-9, gong2025retrospectiveanalysisof pages 1-2)

8. Temporal development (natural history)

While gonadal fate is determined prenatally, ascertainment is typically: - Adolescence/adulthood due to infertility/hypogonadism/gynecomastia in those with typical male genitalia. (terribile201946xxtesticulardisorder pages 1-3, ferrari2024testiculardifferentiationin pages 1-2) - Infancy/childhood in those with ambiguous genitalia/hypospadias/cryptorchidism. (gong2025retrospectiveanalysisof pages 1-2)

A typical trajectory includes progressive testicular dysfunction with hypergonadotropic hypogonadism and infertility/azoospermia. (terribile201946xxtesticulardisorder pages 7-9, li201446xxtesticulardisorder pages 1-2)


9. Inheritance and population

9.1 Epidemiology

  • Incidence is commonly cited as ~1:20,000–25,000 newborn males. (luo2026raresrynegative46xx pages 4-5, terribile201946xxtesticulardisorder pages 1-3, ferrari2024testiculardifferentiationin pages 1-2)
  • Ferrari 2024 further reports it accounts for ~2% of male infertility. (ferrari2024testiculardifferentiationin pages 1-2)

9.2 Inheritance pattern

Most SRY+ cases are typically sporadic de novo chromosomal rearrangements (SRY translocation during paternal meiosis) rather than classical Mendelian inheritance. (terribile201946xxtesticulardisorder pages 7-9)

Some SRY-negative genetic causes can follow Mendelian inheritance patterns depending on the gene (e.g., recessive RSPO1/WNT4-related syndromes versus de novo CNVs), but inheritance details vary by molecular diagnosis and were not comprehensively quantifiable from the retrieved excerpts. (abalı2024diagnosisandmanagement pages 14-14, abalı2024diagnosisandmanagement pages 1-2)


10. Diagnostics

10.1 Core diagnostic approach (real-world implementation)

Clinical and endocrine evaluation plus mandatory cytogenetic/genetic workup is standard: - Semen analysis and karyotype are emphasized as key initial tests in adults presenting with infertility. (terribile201946xxtesticulardisorder pages 9-11, terribile201946xxtesticulardisorder pages 1-3) - SRY detection via PCR and/or FISH is used to classify SRY+ vs SRY− cases and can guide downstream testing. (terribile201946xxtesticulardisorder pages 9-11, li201446xxtesticulardisorder pages 1-2) - Abdominal/pelvic ultrasound is used to evaluate for residual Müllerian structures. (terribile201946xxtesticulardisorder pages 9-11, terribile201946xxtesticulardisorder pages 1-3)

10.2 Recommended genetic testing workflow (DSD best practice)

A widely cited expert position paper (EU COST DSDnet) supports a stepwise approach: - “Ascertainment of the karyotpye defines one of the three major diagnostic DSD subclasses and is therefore the mandatory initial step.” (Audí 2018, Eur J Endocrinol; published 2018-10; URL https://doi.org/10.1530/eje-18-0256) (audı2018geneticsinendocrinology pages 1-6) - After karyotype: molecular testing for monogenic causes and/or CNVs; panels are increasingly used early; WES/WGS are transitioning into routine and also enable novel-gene discovery but require cautious interpretation. (audı2018geneticsinendocrinology pages 6-9, audı2018geneticsinendocrinology pages 1-6)

A newborn-focused review also emphasizes modern implementation choices: - targeted NGS gene panels for coverage/limited incidental findings; escalation to WES/WGS for complex cases; and that trio WES can increase diagnostic yield. (ibba2022differencesofsex pages 18-21)

10.3 Differential diagnosis

Key distinctions: - 46,XX DSD due to androgen excess (e.g., CAH) typically has normal ovarian development and differs mechanistically from XX testicular differentiation. (abalı2024diagnosisandmanagement pages 1-2) - Ovotesticular DSD (46,XX OT‑DSD) overlaps substantially and may be part of the same mechanistic spectrum; Ferrari 2024 cites OT‑DSD as rare (~1:100,000 births) and most often 46,XX (65–90%). (ferrari2024testiculardifferentiationin pages 2-4)


11. Outcome / prognosis

11.1 Survival and mortality

No disease-specific mortality signal is emphasized in the retrieved excerpts; the major morbidity is reproductive/endocrine.

11.2 Morbidity and functional outcomes

  • Fertility: azoospermia is common; fertility is typically severely impaired. (li201446xxtesticulardisorder pages 1-2, terribile201946xxtesticulardisorder pages 1-3)
  • Endocrine: progressive testicular failure and hypergonadotropic hypogonadism are common, requiring monitoring and sometimes hormone therapy. (terribile201946xxtesticulardisorder pages 7-9, gong2025retrospectiveanalysisof pages 1-2)
  • Psychosocial/quality of life: DSD care guidelines emphasize multidisciplinary management, but validated QoL measures specific to 46,XX T‑DSD were not extractable from the retrieved sources.

12. Treatment

12.1 Management principles (current practice)

There are no disease‑modifying molecular therapies in routine clinical care; management is supportive and individualized.

Infertility counseling / assisted reproduction: - “Testicular sperm extraction is not recommended, and adoption or in vitro fertilization with a sperm donor are fertility options.” (Terribile 2019; URL https://doi.org/10.3390/medicina55070371) (terribile201946xxtesticulardisorder pages 7-9)

Endocrine management: - monitor for puberty/testosterone insufficiency and hypergonadotropic hypogonadism; in pediatric cohorts, early gonadectomy in female-reared children prevents spontaneous puberty and can necessitate sex-hormone replacement planning. (gong2025retrospectiveanalysisof pages 1-2)

Surgical management (when indicated): - repair of hypospadias/cryptorchidism; management of Müllerian remnants/prostatic utricle in specific anatomic presentations; endoscopic evaluation was recommended preoperatively for detecting prostatic utricle in SRY‑negative cases. (wei2022duplicationofsox3 pages 1-3)

Tumor-risk assessment: - individualized; pediatric series found no tumors on biopsy but OCT3/4 positivity in a minority. (gong2025retrospectiveanalysisof pages 1-2)

Suggested MAXO terms (examples for knowledge base mapping): - MAXO:0000058 hormone replacement therapy - MAXO:0001176 genetic counseling - MAXO:0001020 orchidopexy - MAXO:0001095 hypospadias repair - MAXO:0000931 gonadectomy (select cases)

12.2 Clinical trials

A clinicaltrials.gov search identified no interventional trials specifically targeting 46,XX testicular DSD; retrieved trials were not disease‑specific (e.g., decision-support for parents of children with rare disease). (NCT01875640 retrieved, but not specific to 46,XX T‑DSD; tool output)


13. Prevention

Primary prevention is not currently feasible for most cases because many are de novo chromosomal rearrangements. Secondary/tertiary prevention focuses on: - early recognition of ambiguous genitalia presentations; - timely genetic diagnosis to guide anticipatory endocrine follow-up and fertility counseling. (audı2018geneticsinendocrinology pages 6-9, audı2018geneticsinendocrinology pages 1-6)


14. Other species / natural disease

A naturally occurring XX DSD subtype exists in dogs that is phenotypically similar to the human SRY‑negative XX DSD spectrum. In one study: - “This is a naturally occurring disorder in humans (Homo sapiens) and dogs (C. familiaris). Phenotypes in the canine XX DSD model are strikingly similar to those of the human XX DSD subtype.” (Meyers‑Wallen 2017, PLoS ONE; published 2017-10; URL https://doi.org/10.1371/journal.pone.0186331) ()

The same study identified a variant upstream of SOX9 and found embryonic gonads had RSPO1 downregulation, proposing upstream lesions causing “epigenomic gonadal mosaicism.” ()

(Note: was introduced via paper_search results but not previously listed in gathered evidence; therefore it is not citable unless present in context IDs. It is not in the citable list above, so it is not used further.)


15. Model organisms

Ferrari 2024 anchors gene-network understanding using mammalian developmental genetics, describing early gonadal ridge formation genes and downstream testis/ovary antagonism. (ferrari2024testiculardifferentiationin pages 2-4)

Beyond descriptive models, the canine XX DSD model provides a naturally occurring system to study SRY‑negative XX testicular/ovotesticular development and the RSPO1/WNT axis. (; not citable here, see note above)


Summary table

The following table provides a compact synthesis of key facts (names, incidence, SRY distribution, presentation, and management).

Item Evidence-based details Key sources (pqac ids)
Disease names / synonyms 46,XX testicular disorder of sex development; 46,XX testicular DSD; 46,XX male syndrome; XX male syndrome; 46,XX testicular difference of sex development (li201446xxtesticulardisorder pages 1-2, terribile201946xxtesticulardisorder pages 1-3, grinspon2016disordersofsex pages 1-2)
Epidemiology Rare condition with reported incidence about 1:20,000-25,000 male newborns; estimated to account for ~2% of male infertility. A pediatric testicular/ovotesticular DSD series cited ~1:100,000 births for the broader childhood TDSD/OTDSD grouping (luo2026raresrynegative46xx pages 4-5, terribile201946xxtesticulardisorder pages 1-3, ferrari2024testiculardifferentiationin pages 1-2, gong2025retrospectiveanalysisof pages 1-2)
SRY-positive vs SRY-negative Literature commonly reports ~80-90% SRY-positive and ~10-20% SRY-negative among 46,XX testicular DSD cases. In one systematic review, SRY was detected in 51/57 cases, usually on Xp. In a pediatric 52-case TDSD/OTDSD series, SRY-negative cases predominated; only 4/52 had SRY in peripheral blood and 0/8 tissue samples were SRY-positive (terribile201946xxtesticulardisorder pages 7-9, li201446xxtesticulardisorder pages 1-2, terribile201946xxtesticulardisorder pages 1-3, gong2025retrospectiveanalysisof pages 1-2, wei2022duplicationofsox3 pages 1-3)
Typical age / presentation About 80-90% have typical male external genitalia at birth and are often diagnosed after puberty or in adulthood during infertility workup, hypogonadism, or gynecomastia evaluation. A minority (~15%) present at birth/childhood with ambiguous genitalia, hypospadias, cryptorchidism, or micropenis. In the pediatric single-center cohort, median age at first presentation was 18 months (terribile201946xxtesticulardisorder pages 7-9, terribile201946xxtesticulardisorder pages 1-3, barseghyan2017identificationofgenetic pages 21-26, gong2025retrospectiveanalysisof pages 1-2, ferrari2024testiculardifferentiationin pages 1-2)
Typical phenotype Common findings include normal male phenotype or variable undervirilization, small testes/microorchidism, azoospermia/infertility, hypergonadotropic hypogonadism, gynecomastia, cryptorchidism, hypospadias, and occasionally residual Müllerian structures or prostatic utricle in SRY-negative cases (terribile201946xxtesticulardisorder pages 7-9, li201446xxtesticulardisorder pages 1-2, terribile201946xxtesticulardisorder pages 1-3, wei2022duplicationofsox3 pages 1-3)
Key management pearls Recommended evaluation includes careful genital exam, semen analysis, endocrine testing, karyotype, SRY testing by PCR/FISH, and abdominal ultrasound to assess Müllerian remnants; gonadal biopsy may help define gonadal tissue in selected SRY-negative cases. Genetic/endocrine consultation is recommended. TESE is generally not recommended; fertility options include donor-sperm IVF or adoption. Long-term follow-up should monitor pubertal progression, testicular failure/hypergonadotropic hypogonadism, tumor-risk markers, and individualized gender/psychosocial outcomes (terribile201946xxtesticulardisorder pages 9-11, terribile201946xxtesticulardisorder pages 1-3, wei2022duplicationofsox3 pages 1-3, gong2025retrospectiveanalysisof pages 1-2, audı2018geneticsinendocrinology pages 1-6)

Table: This table provides a compact evidence-based summary of names, epidemiology, SRY status distribution, presentation patterns, and practical management points for 46,XX testicular DSD. It is useful as a quick reference before the full narrative report.


Recent developments (prioritizing 2023–2024)

  1. 2024 synthesis of genetic causes: Ferrari et al. (Frontiers in Endocrinology, 2024-04, https://doi.org/10.3389/fendo.2024.1385901) consolidates known genetic mechanisms and emphasizes that many cases remain genetically unresolved; it also provides epidemiologic and presentation statistics (incidence ~1:20,000–1:25,000; ~2% of male infertility; typical male genitalia at birth with later diagnosis). (ferrari2024testiculardifferentiationin pages 1-2, ferrari2024testiculardifferentiationin pages 2-4)

  2. 2024 clinical perspective on non‑CAH 46,XX DSD: Abalı & Guran (Frontiers in Endocrinology, 2024-05, https://doi.org/10.3389/fendo.2024.1354759) provides an updated gene list spanning CNVs and sequence variants implicated in 46,XX testicular/ovotesticular DSD and highlights management uncertainty around gonadal function and gender outcomes. (abalı2024diagnosisandmanagement pages 1-2)

  3. 2023 focus on nuclear receptor genes and phenotypic variability: Hattori & Fukami (Biomolecules, 2023-04, https://doi.org/10.3390/biom13040691) situates NR5A1/NR0B1/NR2F2 as key nuclear receptor genes in atypical testicular development and explicitly notes NR5A1 variants in both 46,XY and 46,XX testicular/ovotesticular DSD, with possible oligogenic contributions. (hattori2023nuclearreceptorgene pages 1-3)


Limitations of this run

  • Formal mappings to OMIM/Orphanet/MONDO/ICD/MeSH identifiers could not be provided with tool-citable evidence.
  • Some additional potentially relevant papers were discovered by search but not fully retrieved/validated for citation in this run.

References

  1. (terribile201946xxtesticulardisorder pages 1-3): Marco Terribile, Marco Stizzo, Celeste Manfredi, Carmelo Quattrone, Francesco Bottone, Dario Ranieri Giordano, Giuseppe Bellastella, Davide Arcaniolo, and Marco De Sio. 46,xx testicular disorder of sex development (dsd): a case report and systematic review. Medicina, 55:371, Jul 2019. URL: https://doi.org/10.3390/medicina55070371, doi:10.3390/medicina55070371. This article has 81 citations.

  2. (ferrari2024testiculardifferentiationin pages 1-2): Maria Tereza Martins Ferrari, Elinaelma Suelane do Nascimento Silva, Mirian Yumie Nishi, Rafael Loch Batista, Berenice Bilharinho Mendonca, and Sorahia Domenice. Testicular differentiation in 46,xx dsd: an overview of genetic causes. Frontiers in Endocrinology, Apr 2024. URL: https://doi.org/10.3389/fendo.2024.1385901, doi:10.3389/fendo.2024.1385901. This article has 20 citations.

  3. (li201446xxtesticulardisorder pages 1-2): Tian-Fu Li, Qiu-Yue Wu, Cui Zhang, Wei-Wei Li, Qing Zhou, Wei-Jun Jiang, Ying-Xia Cui, Xin-Yi Xia, and Yi-Chao Shi. 46,xx testicular disorder of sexual development with sry-negative caused by some unidentified mechanisms: a case report and review of the literature. BMC Urology, Dec 2014. URL: https://doi.org/10.1186/1471-2490-14-104, doi:10.1186/1471-2490-14-104. This article has 46 citations and is from a peer-reviewed journal.

  4. (gong2025retrospectiveanalysisof pages 1-2): Yan Gong, Xiaoqin Yin, Jing Xu, Yan Li, Qingxu Liu, Shasha Zhou, Fei Wang, Yiqing Lyu, Sheng Guo, Wenyan Huang, and Pin Li. Retrospective analysis of children with 46,xx testicular/ovotesticular dsd: a 10-year single-center experience. Frontiers in Endocrinology, May 2025. URL: https://doi.org/10.3389/fendo.2025.1571467, doi:10.3389/fendo.2025.1571467. This article has 2 citations.

  5. (ferrari2024testiculardifferentiationin pages 2-4): Maria Tereza Martins Ferrari, Elinaelma Suelane do Nascimento Silva, Mirian Yumie Nishi, Rafael Loch Batista, Berenice Bilharinho Mendonca, and Sorahia Domenice. Testicular differentiation in 46,xx dsd: an overview of genetic causes. Frontiers in Endocrinology, Apr 2024. URL: https://doi.org/10.3389/fendo.2024.1385901, doi:10.3389/fendo.2024.1385901. This article has 20 citations.

  6. (abalı2024diagnosisandmanagement pages 1-2): Zehra Yavas Abalı and Tulay Guran. Diagnosis and management of non-cah 46,xx disorders/differences in sex development. Frontiers in Endocrinology, May 2024. URL: https://doi.org/10.3389/fendo.2024.1354759, doi:10.3389/fendo.2024.1354759. This article has 11 citations.

  7. (terribile201946xxtesticulardisorder pages 7-9): Marco Terribile, Marco Stizzo, Celeste Manfredi, Carmelo Quattrone, Francesco Bottone, Dario Ranieri Giordano, Giuseppe Bellastella, Davide Arcaniolo, and Marco De Sio. 46,xx testicular disorder of sex development (dsd): a case report and systematic review. Medicina, 55:371, Jul 2019. URL: https://doi.org/10.3390/medicina55070371, doi:10.3390/medicina55070371. This article has 81 citations.

  8. (wei2022duplicationofsox3 pages 1-3): Jiansheng Wei, Changrong Liu, Minyan Zhang, Shen Liu, Junjie Fu, and Peng Lin. Duplication of sox3 in an sry-negative 46,xx male with prostatic utricle: case report and literature review. BMC Medical Genomics, Sep 2022. URL: https://doi.org/10.1186/s12920-022-01347-0, doi:10.1186/s12920-022-01347-0. This article has 19 citations and is from a peer-reviewed journal.

  9. (baetens2017nr5a1isa pages 1-2): Dorien Baetens, Hans Stoop, Frank Peelman, Anne-Laure Todeschini, Toon Rosseel, Frauke Coppieters, Reiner A. Veitia, Leendert H.J. Looijenga, Elfride De Baere, and Martine Cools. Nr5a1 is a novel disease gene for 46,xx testicular and ovotesticular disorders of sex development. Genetics in Medicine, 19:367-376, Apr 2017. URL: https://doi.org/10.1038/gim.2016.118, doi:10.1038/gim.2016.118. This article has 152 citations and is from a highest quality peer-reviewed journal.

  10. (bashamboo2016arecurrentp.arg92trp pages 1-3): Anu Bashamboo, Patricia A. Donohoue, Eric Vilain, Sandra Rojo, Pierre Calvel, Sumudu N. Seneviratne, Federica Buonocore, Hayk Barseghyan, Nathan Bingham, Jill A. Rosenfeld, Surya Narayan Mulukutla, Mahim Jain, Lindsay Burrage, Shweta Dhar, Ashok Balasubramanyam, Brendan Lee, Marie-Charlotte Dumargne, Caroline Eozenou, Jenifer P. Suntharalingham, KSH de Silva, Lin Lin, Joelle Bignon-Topalovic, Francis Poulat, Carlos F. Lagos, Ken McElreavey, and John C. Achermann. A recurrent p.arg92trp variant in steroidogenic factor-1 (nr5a1) can act as a molecular switch in human sex development. Human Molecular Genetics, 25:3446-3453, Jul 2016. URL: https://doi.org/10.1093/hmg/ddw186, doi:10.1093/hmg/ddw186. This article has 152 citations and is from a domain leading peer-reviewed journal.

  11. (terribile201946xxtesticulardisorder pages 9-11): Marco Terribile, Marco Stizzo, Celeste Manfredi, Carmelo Quattrone, Francesco Bottone, Dario Ranieri Giordano, Giuseppe Bellastella, Davide Arcaniolo, and Marco De Sio. 46,xx testicular disorder of sex development (dsd): a case report and systematic review. Medicina, 55:371, Jul 2019. URL: https://doi.org/10.3390/medicina55070371, doi:10.3390/medicina55070371. This article has 81 citations.

  12. (hattori2023nuclearreceptorgene pages 1-3): Atsushi Hattori and Maki Fukami. Nuclear receptor gene variants underlying disorders/differences of sex development through abnormal testicular development. Biomolecules, 13:691, Apr 2023. URL: https://doi.org/10.3390/biom13040691, doi:10.3390/biom13040691. This article has 11 citations.

  13. (luo2026raresrynegative46xx pages 4-5): Jianxu Luo, Fuxin Huang, Jianlin Li, Enhao Mo, Hu Wang, Jianyong Zhang, Caifeng Pang, Dezheng Lei, and Jiabo Chen. Rare sry-negative 46,xx disorder of sex development with male phenotype and ectopic gonads: a case report. Frontiers in Endocrinology, Apr 2026. URL: https://doi.org/10.3389/fendo.2026.1829751, doi:10.3389/fendo.2026.1829751. This article has 0 citations.

  14. (abalı2024diagnosisandmanagement pages 14-14): Zehra Yavas Abalı and Tulay Guran. Diagnosis and management of non-cah 46,xx disorders/differences in sex development. Frontiers in Endocrinology, May 2024. URL: https://doi.org/10.3389/fendo.2024.1354759, doi:10.3389/fendo.2024.1354759. This article has 11 citations.

  15. (audı2018geneticsinendocrinology pages 1-6): L. Audı́, S. Ahmed, N. Krone, M. Cools, K. McElreavey, P. Holterhus, A. Greenfield, A. Bashamboo, O. Hiort, S. Wudy, and R. McGowan. Genetics in endocrinology: approaches to molecular genetic diagnosis in the management of differences/disorders of sex development (dsd): position paper of eu cost action bm 1303 ‘dsdnet’. European Journal of Endocrinology, 179:R197-R206, Oct 2018. URL: https://doi.org/10.1530/eje-18-0256, doi:10.1530/eje-18-0256. This article has 140 citations and is from a highest quality peer-reviewed journal.

  16. (audı2018geneticsinendocrinology pages 6-9): L. Audı́, S. Ahmed, N. Krone, M. Cools, K. McElreavey, P. Holterhus, A. Greenfield, A. Bashamboo, O. Hiort, S. Wudy, and R. McGowan. Genetics in endocrinology: approaches to molecular genetic diagnosis in the management of differences/disorders of sex development (dsd): position paper of eu cost action bm 1303 ‘dsdnet’. European Journal of Endocrinology, 179:R197-R206, Oct 2018. URL: https://doi.org/10.1530/eje-18-0256, doi:10.1530/eje-18-0256. This article has 140 citations and is from a highest quality peer-reviewed journal.

  17. (ibba2022differencesofsex pages 18-21): Anastasia IBBA, Marta DEL PISTOIA, Antonio BALSAMO, Federico BARONIO, Donatella CAPALBO, Gianni RUSSO, Luisa DE SANCTIS, and Carla BIZZARRI. Differences of sex development in the newborn: from clinical scenario to molecular diagnosis. Jan 2022. URL: https://doi.org/10.23736/s2724-5276.21.06512-5, doi:10.23736/s2724-5276.21.06512-5. This article has 8 citations.

  18. (grinspon2016disordersofsex pages 1-2): Romina P. Grinspon and Rodolfo A. Rey. Disorders of sex development with testicular differentiation in sry-negative 46,xx individuals: clinical and genetic aspects. Sexual Development, 10:1-11, Apr 2016. URL: https://doi.org/10.1159/000445088, doi:10.1159/000445088. This article has 110 citations and is from a peer-reviewed journal.

  19. (barseghyan2017identificationofgenetic pages 21-26): H Barseghyan. Identification of genetic etiology in disorders of sex development. Unknown journal, 2017.

Artifacts

46,XX Testicular DSD Deep Research Fallback

46,XX Testicular DSD Deep Research Fallback

Provider Attempts

  • 2026-05-08T15:00Z: just research-disorder asta 46_XX_Testicular_DSD failed: ERROR - No research providers available. Please set API keys (no ASTA_API_KEY configured in this environment).
  • 2026-05-08T15:00Z: just research-disorder openai 46_XX_Testicular_DSD failed with the same provider-unavailable error (no OPENAI_API_KEY).
  • 2026-05-08T15:00Z: just research-disorder perplexity 46_XX_Testicular_DSD failed with the same provider-unavailable error (no PERPLEXITY_API_KEY).
  • 2026-05-08T15:00Z: just research-disorder falcon 46_XX_Testicular_DSD failed with the same provider-unavailable error (no provider keys at all, including Edison/Falcon).

just research-providers confirmed no providers are configured in this worktree. No provider-generated research artifact was available to integrate. Curation therefore proceeded from the PubMed-cached abstracts already referenced in kb/disorders/46_XX_Testicular_DSD.yaml, without hand-editing any references_cache/*.md files.

Evidence Scope Used For Curation

  • PMID:31336995 (Terribile et al. 2019, Medicina) — case report + systematic review of 46,XX testicular DSD. Used as the canonical clinical-presentation reference: SRY-positive vs SRY-negative classification, adult presentation with infertility, hypergonadotropic hypogonadism, gynecomastia, small testes, cryptorchidism (~15%) and anterior hypospadias (~10%), and the rationale for long-term testosterone replacement.
  • PMID:36341017 (Kouvidi et al. 2022) — two new cases plus literature review cohort. Used for SRY-translocation epidemiology (84.4% SRY-positive, 98.5% Xp), absence of AZF regions, and quantitative phenotype frequencies in the cohort: small testes (90.2%), small penis (31.8%), gynecomastia (26.8%), poor hair distribution (15.4%). The "small penis (31.8%)" figure is the source for the new Micropenis (HP:0000054) phenotype entry.
  • PMID:25077096 (Lee et al. 2014, Ann Pediatr Endocrinol Metab) — Korean boy with 46,XX testicular DSD caused by SOX9 duplication. Supports the SRY-negative SOX9 gain-of-function mechanism in which duplications upstream of SOX9 drive ectopic testis determination in 46,XX gonads.
  • PMID:34050715 (Qian et al. 2021) — whole-genome sequencing of an SRY-negative 46,XX ovotesticular DSD case identifying a cryptic SOX9 regulatory-element duplication. Reinforces the SOX9 enhancer-duplication mechanism and shows how cryptic non-coding variants can be missed by standard cytogenetics.
  • PMID:36064700 (Wei et al. 2022) — SRY-negative 46,XX male with SOX3 duplication and prostatic utricle. Supports SOX3 duplication as an alternative SRY-independent driver of testis determination, expanding the set of SRY-negative genetic etiologies beyond SOX9.
  • PMID:29575617 (Tallapaka et al. 2018, Am J Med Genet A) — novel RSPO1 mutation causing SRY-negative 46,XX testicular DSD with palmoplantar keratoderma. Defines the RSPO1-associated subtype and establishes palmoplantar hyperkeratosis as the pathognomonic extra-gonadal feature that clinically distinguishes RSPO1 cases from other SRY-negative etiologies.

Curation Conclusions

46,XX testicular disorder of sex development is a sex-reversal phenotype in which 46,XX gonads commit to the testis pathway despite the absence of a typical Y chromosome. Two broad mechanistic classes account for nearly all cases. In SRY-positive 46,XX testicular DSD (~85% of patients), aberrant paternal-meiosis recombination translocates SRY onto the X chromosome (most commonly Xp22), with rare autosomal landings; the translocated SRY drives Sertoli-cell specification and the canonical SOX9-mediated testis cascade, producing essentially complete masculinization at birth and an adult presentation dominated by hypergonadotropic hypogonadism, azoospermia, and infertility. In SRY-negative 46,XX testicular DSD, testis determination is driven by genetic perturbations that bypass SRY: gain-of-function copy-number gains around SOX9 (including cryptic enhancer duplications detectable only by whole-genome sequencing), SOX3 duplications that act as ectopic SRY-like inducers, and biallelic loss of RSPO1 that disrupts the WNT/RSPO1/CTNNB1 ovarian-determining program and permits default testis differentiation. The RSPO1 subtype is uniquely identifiable by palmoplantar keratoderma — the clinically distinguishing extra-gonadal feature.

Regardless of upstream genetic mechanism, the downstream gonadal pathology converges on dysgenetic testes lacking germ-cell development. Loss of the AZF regions on Yq and absence of normal seminiferous tubule architecture result in azoospermia in essentially all affected individuals; testicular sperm extraction is generally unsuccessful. Sertoli-cell and Leydig-cell function is partially preserved in childhood (giving rise to externally masculine genitalia and pubertal initiation), but post-pubertal Leydig-cell insufficiency manifests as low testosterone with elevated LH/FSH — hypergonadotropic hypogonadism — driving the adult clinical phenotype: small testes (~90% of patients), small penis (~32%), gynecomastia (~27%), sparse body hair (~15%), reduced bone mineral density, and infertility. SRY-negative cases more commonly show ambiguous or undermasculinized external genitalia at birth (hypospadias, cryptorchidism), reflecting attenuated fetal androgen production, and may present in childhood rather than adulthood.

Treatment is supportive and lifelong. Long-term testosterone replacement (captured here as MAXO:0000058 pharmacotherapy with CHEBI:17347 testosterone as the therapeutic agent) addresses hypogonadism, supports secondary sexual characteristics, and protects bone health. Genetic counseling addresses the rare familial recurrence risk (notably for RSPO1 biallelic families and inherited SOX3/SOX9 CNVs) and the reproductive limitations. Assisted-reproduction options are restricted to donor sperm with intrauterine insemination or IVF, since affected individuals are azoospermic. Surgical correction is appropriate for hypospadias and cryptorchidism in SRY-negative presentations.